

AUTHOR INDEX FOR VOLUME 46

A

- Abdel-Razzak, Z., Corcos, L., Fautrel, A., Campion, J.-P., and Guilouzo, A. Transforming growth factor- β 1 down-regulates basal and polycyclic aromatic hydrocarbon-induced cytochromes P-450 1A1 and 1A2 in adult human hepatocytes in primary culture, 1100
- Abraham, C., *see* Morain, P., 732
- Achkar, C., *see* Chen, M., 88
- Adan, R. A. H., Cone, R. D., Burbach, J. P. H., and Gispen, W. H. Differential effects of melanocortin peptides on neural melanocortin receptors, 1182
- Adesnik, M., *see* Shaw, P. M., 79
- Agbaria, R., *see* Zhang, H., 1063
- Ahlers, A., Belka, C., Gaestel, M., Lamping, N., Sott, C., Herrmann, F., and Brach, M. A. Interleukin-1-induced intracellular signaling pathways converge in the activation of mitogen-activated protein kinase and mitogen-activated protein kinase-activated protein kinase 2 and the subsequent phosphorylation of the 27-kilodalton heat shock protein in monocytic cells, 1077
- Ahluwalia, G. S., Cooney, D. A., Shirasaka, T., Mitsuya, H., Driscoll, J. S., and Johns, D. G. Enhancement by 2'-deoxycoformycin of the 5'-phosphorylation and anti-human immunodeficiency virus activity of 2',3'-dideoxyadenosine and 2'- β -fluoro-2',3'-dideoxyadenosine, 1002
- Ahmad, S., *see* Yang, S.-G., 256
- Ailhaud, G., *see* Ibrahimi, A., 1070
- Akeson, M., *see* Benya, R. V., 495
- Albano, E., *see* Moncada, C., 786
- Albuquerque, E. X., *see* Nelson, M. E., 151
- Alexandrova, N., *see* Ben-Baruch, N., 73
- Alifimoff, J. K., *see* Firestone, L. L., 508
- Allan, W. P., *see* Ritke, M. K., 58, 605
- Alvarez, M., *see* Lee, J.-S., 627
- Amara, S. G., *see* Clark, J. A., 550
- Amri, E.-Z., *see* Ibrahimi, A., 1070
- Anand, R., *see* Peng, X., 523
- Anderson, D. E., *see* Pou, S., 709
- Anthony, M. L., Sweatman, B. C., Beddell, C. R., Lindon, J. C., and Nicholson, J. K. Pattern recognition classification of the site of nephrotoxicity based on metabolic data derived from proton nuclear magnetic resonance spectra of urine, 199
- Asghari, V., Schoots, O., Van Kats, S., Ohara, K., Jovanovic, V., Guan, H.-C., Bunzow, J. R., Petronis, A., and Van Tol, H. H. M. Dopamine D4 receptor repeat: analysis of different native and mutant forms of the human and rat gene, 364
- Ashford, M. L. J., *see* Lee, K., 176
- Aylwin, M. L., and White, M. M. Gating properties of mutant acetylcholine receptors, 1149
- Baker, R., *see* Patel, S., 943
- Bakthavachalam, V., *see* Ivkovic, B., 15
- Banfi, P., Lanzi, C., Falvella, F. S., Gariboldi, M., Gambetta, R. A., and Dragani, T. A. The daunorubicin-binding protein of *M.* 54,000 is an aldehyde dehydrogenase and is down-regulated in mouse liver tumors and in tumor cell lines, 896
- Bangalore, R., Baidur, N., Rutledge, A., Triggie, D. J., and Kass, R. S. L-Type calcium channels: asymmetrical intramembrane binding domain revealed by variable length, permanently charged 1,4-dihydropyridines, 660
- Bard, J. A., *see* Laz, T. M., 414
- Barker, E. L., Kimmel, H. L., and Blakely, R. D. Chimeric human and rat serotonin transporters reveal domains involved in recognition of transporter ligands, 799
- Barker, J. L., *see* Liu, Q.-Y., 1197
- Barone, L. R., *see* Speicher, L. A., 866
- Barr, A. J., and Watson, S. P. Protein kinase C mediates delayed inhibitory feedback regulation of human neurokinin type 1 receptor activation of phospholipase C in UC11 astrocytoma cells, 266
- Barret, J.-M., Calsou, P., Larsen, A. K., and Salles, B. A cisplatin-resistant murine leukemia cell line exhibits increased topoisomerase II activity, 431
- Barrett, K. E., *see* Schultz, C., 702
- Bates, S. E., *see* Lee, J.-S., 627
- Battaglia, G., *see* Pinto, W., 1111
- Batley, J. F., *see* Benya, R. V., 235, 495
- Bean, B. P., *see* Kuo, C.-C., 716
- Beavo, J. A., Conti, M., and Heaslip, R. J. Multiple cyclic nucleotide phosphodiesterases, 399
- Beddell, C. R., *see* Anthony, M. L., 199
- Befort, K., *see* Simonin, F., 1015
- Belelli, D., *see* Hawkinson, J. E., 977
- Belka, C., *see* Ahlers, A., 1077
- Ben-Baruch, N., Reinhold, W. C., Alexandrova, N., Ichinose, I., Blake, M., Trepel, J. B., and Zajac-Kaye, M. *c-myc* Down-regulation in suramin-treated HL60 cells precedes growth inhibition but does not trigger differentiation, 73
- Benchekroun, M. N., Schneider, E., Safa, A. R., Townsend, A. J., and Sinha, B. K. Mechanisms of resistance to ansamycin antibiotics in human breast cancer cell lines, 677
- Benya, R. V., Akeson, M., Mrozinski, J., Jensen, R. T., and Batley, J. F. Internalization of the gastrin-releasing peptide receptor is mediated by both phospholipase C-dependent and -independent processes, 495
- Benya, R. V., Fathi, Z., Kusui, T., Pradhan, T., Batley, J. F., and Jensen, R. T. Gastrin-releasing peptide receptor-induced internalization, down-regulation, desensitization, and growth: possible role for cyclic AMP, 235
- Berg, K. A., Clarke, W. P., Sailstad, C., Saltzman, A., and Maayani, S. Signal transduction differences between 5-hydroxytryptamine type 2A and Type 2C receptor systems, 477
- Berger, S. P., Farrell, K., Conant, D., Kempner, E. S., and Paul, S. M. Radiation inactivation studies of the dopamine reuptake transporter protein, 726
- Berkowitz, D. E., *see* Price, D. T., 221
- Berleth, E., *see* Zaleskis, G., 901
- Bertilsson, L., *see* Johansson, I., 452
- Birnbaumer, L., *see* Zhu, X., 460
- Birnbaumer, M., *see* Zhu, X., 460

B

- Badman, G. T., *see* Muzzin, P., 357
- Baez, M., *see* Kursar, J. D., 227
- Bailey, T. J., *see* Regan, J. W., 213
- Bailly, C., Donkor, I. O., Gentle, D., Thornalley, M., and Waring, M. J. Sequence-selective binding to DNA of *Cis*- and *Trans*-butamidine analogues of the anti-*Pneumocystis carinii* pneumonia drug pentamidine, 313
- Baidur, N., *see* Bangalore, R., 660

- Blaisdell, J., *see* de Moraes, S. M. F., 594
 Blake, M., *see* Ben-Baruch, N., 73
 Blakely, R. D., *see* Barker, E. L., 799
 Blanton, M. P., Li, Y.-M., Stimson, E. R., Maggio, J. E., and Cohen, J. B. Agonist-induced photoincorporation of a *p*-benzoylphenylalanine derivative of substance P into membrane-spanning region 2 of the *Torpedo* nicotinic acetylcholine receptor δ subunit, 1048
 Bloomenthal, A. B., Goldwater, E., Pritchett, D. B., and Harrison, N. L. Biphasic modulation of the strychnine-sensitive glycine receptor by Zn^{2+} , 1156
 Blumberg, P. M., *see* Kazanietz, M. G., 374
 Blumberg, P. M., *see* Szallasi, Z., 840
 Bochkov, V. N., *see* Tkachuk, V. A., 1129
 Bogardus, A. M., *see* Regan, J. W., 213
 Bonanno, G., *see* Gemignani, A., 558
 Bonnafous, J.-C., *see* Nouet, S., 693
 Boring, D., *see* Pinto, J. C., 516
 Bosch, S., *see* Ivkovic, B., 15
 Boss, O., *see* Muzzin, P., 357
 Bosse, R., *see* Liebmann, C., 949
 Bouchard, B., *see* Le Panse, R., 445
 Boulanger, C. M., *see* Scott-Burden, T., 274
 Bourrain, S., *see* Patel, S., 943
 Boyer, J. L., *see* Filtz, T. M., 8
 Brach, M. A., *see* Ahlers, A., 1077
 Brady, K. D., Han, B., and Tashjian, A. H., Jr. Kinetics and reversibility of thyrotropin-releasing hormone-stimulated guanine nucleotide exchange in membranes from GH_4C_1 cells, 644
 Branchek, T. A., *see* Laz, T. M., 414
 Brown, J. H., *see* Nieto, M., 406
 Bruggemann, E. P., *see* Morris, D. I., 329
 Buller, A. L., Hastings, G. A., Kirkness, E. F., and Fraser, C. M. Site-directed mutagenesis of *N*-linked glycosylation sites on the γ -aminobutyric acid type A receptor α_1 subunit, 858
 Bunzow, J. R., *see* Asghari, V., 364
 Burbach, J. P. H., *see* Adan, R. A. H., 1182
 Burnett, V. L., *see* Hasler, J. A., 338
 Busch, A. E., Herzer, T., Wagner, C. A., Schmidt, F., Raber, G., Waldegger, S., and Lang, F. Positive regulation by chloride channel blockers of I_{K} channels expressed in *Xenopus* oocytes, 750
 Butt, E., *see* Meinecke, M., 283
- C**
- Cachelin, A. B., and Rust, G. Unusual pharmacology of (+)-tubocurarine with rat neuronal nicotinic acetylcholine receptors containing β_4 subunits, 1168
 Calsou, P., *see* Barret, J.-M., 431
 Camerino, D. C., *see* Tricarico, D., 754
 Campion, J.-P., *see* Abdel-Razzak, Z., 1100
 Cantello, B. C. C., *see* Muzzin, P., 357
 Cantrell, C. H., *see* Pinto, J. C., 516
 Caput, D., *see* Farges, R., 1160
 Cardarelli, C., *see* Morris, D. I., 329
 Caron, M. G., *see* Robinson, S. W., 352
 Caron, M. G., *see* Silvia, C. P., 51
 Casabianca-Pignède, M.-R., *see* Khélifa, T., 323
 Castle, N. A., Fadous, S. R., Logothetis, D. E., and Wang, G. K. 4-Aminopyridine binding and slow inactivation are mutually exclusive in rat Kv1.1 and *Shaker* potassium channels, 1175
 Cawthorne, M. A., *see* Ibrahim, A., 1070
 Cawthorne, M. A., *see* Muzzin, P., 357
 Chakraborty, T., *see* Meinecke, M., 283
 Challiss, R. A. J., *see* Jenkinson, S., 1138
 Chamulitrat, W., Jordan, S. J., and Mason, R. P. Nitric oxide production during endotoxic shock in carbon tetrachloride-treated rats, 391
 Chapman, K. L., *see* Patel, S., 943
 Chari, R. S., *see* Price, D. T., 221
 Chen, C.-M., *see* Perng, M.-D., 612
 Chen, K., Wu, H.-F., Grimsby, J., and Shih, J. C. Cloning of a novel monoamine oxidase cDNA from trout liver, 1226
 Chen, M., Achkar, C., and Gudas, L. J. Enzymatic conversion of retinaldehyde to retinoic acid by cloned murine cytosolic and mitochondrial aldehyde dehydrogenases, 88
 Cheng, T.-J., *see* Perng, M.-D., 612
 Chiappinelli, V. A., *see* Weaver, W. R., 993
 Chignell, C. F., *see* Hayden, P. J., 186
 Christopoulos, A., and Mitchelson, F. Assessment of the allosteric interactions of the bisquaternary heptane-1,7-bis(dimethyl-3'-phthalimidopropyl)ammonium bromide at M_1 and M_2 muscarine receptors, 105
 Clark, J. A., and Amara, S. G. Stable expression of a neuronal γ -aminobutyric acid transporter, GAT-3, in mammalian cells demonstrates unique pharmacological properties and ion dependence, 550
 Clarke, W. P., *see* Berg, K. A., 477
 Cohen, J. B., *see* Blanton, M. P., 1048
 Collins, J. M., *see* Klecker, R. W., 1204
 Conant, D., *see* Berger, S. P., 726
 Cone, R. D., *see* Adan, R. A. H., 1182
 Conti, M., *see* Beavo, J. A., 399
 Cook, J. M., *see* Wigler, P. W., 563
 Cooney, D. A., *see* Ahluwalia, G. S., 1002
 Cooney, D. A., *see* Zhang, H., 1063
 Corcos, L., *see* Abdel-Razzak, Z., 1100
 Couceyro, P., Pollock, K. M., Drews, K., and Douglass, J. Cocaine differentially regulates activator protein-1 mRNA levels and DNA-binding complexes in the rat striatum and cerebellum, 667
 Coulomb, B., *see* Le Panse, R., 445
 Coutsogeorgopoulos, C., *see* Kallia-Raftopoulos, S., 1009
- D**
- Damjanovich, S., *see* Gáspár, R., Jr., 762
 Delesque, N., *see* Vidal, C., 97
 de Moraes, S. M. F., Wilkinson, G. R., Blaisdell, J., Meyer, U. A., Nakamura, K., and Goldstein, J. A. Identification of a new genetic defect responsible for the polymorphism of (*S*)-mephentoin metabolism in Japanese, 594
 De Nanteuil, G., *see* Morain, P., 732
 Denning, M. F., *see* Szallasi, Z., 840
 Dettbarn, C., Györke, S., and Palade, P. Many agonists induce "quantal" Ca^{2+} release or adaptive behavior in muscle ryanodine receptors, 502
 De Weille, J., *see* Guillemare, E., 139
 Díaz, R. S., and Monreal, J. Thallium mediates rapid chloride/hydroxyl ion exchange through myelin lipid bilayers, 1210
 Diaz-Araújo, H., *see* Wigler, P. W., 563
 Dilger, J. P., and Vidal, A. M. Cooperative interactions between general anesthetics and QX-222 within the pore of the acetylcholine receptor ion channel, 169
 Dive, C., *see* Ritke, M. K., 605
 Diz, D., *see* Ivkovic, B., 15
 Dlugosz, A. A., *see* Szallasi, Z., 840
 Dodey, P., *see* Nouet, S., 693
 Donello, J. E., *see* Regan, J. W., 213
 Donkor, I. O., *see* Bailly, C., 313
 Dorai, T., Kobayashi, H., Holland, J. F., and Ohnuma, T. Modulation of platelet-derived growth factor- β mRNA expression and cell growth in a human mesothelioma cell line by a hammerhead ribozyme, 437

- Douglass, J., *see* Couceyro, P., 667
 Dragani, T. A., *see* Banfi, P., 896
 Drews, K., *see* Couceyro, P., 667
 Driscoll, J. S., *see* Ahluwalia, G. S., 1002
 Dubertret, L., *see* Le Panse, R., 445
 Dunlap, V., *see* Liu, Q.-Y., 1197
 Dyroff, M. C., *see* Grimm, S. W., 1090

E

- Ebert, B., Wafford, K. A., Whiting, P. J., Krogsgaard-Larsen, P., and Kemp, J. A. Molecular pharmacology of γ -aminobutyric acid type A receptor agonists and partial agonists in oocytes injected with different α , β , and γ receptor subunit combinations, 957
 Eger, E. I., II, *see* Mihic, S. J., 851
 Ehrke, M. J., *see* Zaleskis, G., 901
 Elizonde, E., *see* Scott-Burden, T., 274
 Ellinwood, E. H., *see* Silvia, C. P., 51
 Elliot, M., *see* Miles, M. F., 873
 Elrod, R. D., *see* Kuestner, R. E., 246
 Emoto, Y., *see* Kharbanda, S., 67
 Enyeart, J. J., *see* Mlinar, B., 743
 Esbenshade, T. A., *see* Minneman, K. P., 929
 Escher, E., *see* Liebmann, C., 949
 Esteve, J.-P., *see* Vidal, C., 97
 Evans, D. M., *see* Pinto, J. C., 516

F

- Fadous, S. R., *see* Castle, N. A., 1175
 Faiman, M. D., *see* Madan, A., 1217
 Fairbairn, C. E., *see* Regan, J. W., 213
 Falvella, F. S., *see* Banfi, P., 896
 Farb, D. H., *see* Gyenes, M., 542
 Farb, D. H., *see* Park-Chung, M., 146
 Farber, J. L., *see* Mizumoto, K., 890
 Farges, R., Joseph-Lilauzone, E., Shire, D., Caput, D., Le Fur, G., and Ferrara, P. Site-directed mutagenesis of the peripheral benzodiazepine receptor: identification of amino acids implicated in the binding site of Ro5-4864, 1160
 Farrell, K., *see* Berger, S. P., 726
 Fathi, Z., *see* Benya, R. V., 235
 Fattman, C., *see* Ritke, M. K., 58
 Fautrel, A., *see* Abdel-Razzak, Z., 1100
 Ferguson, J. E., *see* Sasakawa, N., 380
 Ferrara, P., *see* Farges, R., 1160
 Ferrari-Dileo, G., Waelbroeck, M., Mash, D. C., and Flynn, D. D. Selective labeling and localization of the M4 (m4) muscarinic receptor subtype, 1028
 Filtz, T. M., Li, Q., Boyer, J. L., Nicholas, R. A., and Harden, T. K. Expression of a cloned P_{2Y} purinergic receptor that couples to phospholipase C, 8
 Findlay, D. M., *see* Kuestner, R. E., 246
 Firestone, L. L., Alifimoff, J. K., and Miller, K. W. Does general anesthetic-induced desensitization of the *Torpedo* acetylcholine receptor correlate with lipid disordering?, 508
 Fletcher, A. E., *see* Patel, S., 943
 Flynn, D. D., *see* Ferrari-Dileo, G., 1028
 Fojo, A. T., *see* Lee, J.-S., 627
 Fornace, A. J., Jr., *see* Zhang, H., 1063
 Forray, C., *see* Laz, T. M., 414
 Fosset, M., *see* Guillemare, E., 139
 Fraser, C. M., *see* Buller, A. L., 858
 Free, K. E., *see* Hayden, P. J., 186
 Freedman, S. B., *see* Patel, S., 943

G

- Gaestel, M., *see* Ahlers, A., 1077
 Gaillard, D., *see* Ibrahimi, A., 1070
 Gaivin, R., *see* Perez, D. M., 823
 Gambetta, R. A., *see* Banfi, P., 896
 Gao, F., *see* Kazanietz, M. G., 374
 Gao, W.-Y., Johns, D. G., and Mitsuya, H. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2',3'-dideoxynucleosides, 767
 Gariboldi, M., *see* Banfi, P., 896
 Gasiewicz, T. A., *see* Henry, E. C., 1022
 Gáspár, R., Jr., Panyi, G., Ypey, D. L., Krasznai, Z., Vereb, G., Pieri, C., and Damjanovich, S. Effects of bretylium tosylate on voltage-gated potassium channels in human T lymphocytes, 762
 Gavériaux-Ruff, C., *see* Simonin, F., 1015
 Ge, J.-L., *see* Lu, S. C., 578
 Ge, T., *see* Scott-Burden, T., 274
 Geiger, J., *see* Meinecke, M., 283
 Gemignani, A., Paudice, P., Bonanno, G., and Raiteri, M. Pharmacological discrimination between γ -aminobutyric acid type B receptors regulating cholecystokinin and somatostatin release from rat neocortex synaptosomes, 558
 Genieser, H.-G., *see* Schultz, C., 702
 Gentle, D., *see* Bailly, C., 313
 Gerzanich, V., *see* Peng, X., 523
 Giacobino, J.-P., *see* Muzzin, P., 357
 Gibbs, T. T., *see* Gyenes, M., 542
 Gil, D. W., *see* Regan, J. W., 213
 Gilbert, S., *see* Zhu, X., 460
 Gipp, J. J., *see* Mulcahy, R. T., 909
 Gispén, W. H., *see* Adan, R. A. H., 1182
 Glover, E., *see* Poland, A., 915
 Goberna, R., *see* Sánchez-Margalet, V., 24
 Goldstein, D., *see* Nieto, M., 406
 Goldstein, J. A., *see* de Moraes, S. M. F., 594
 Goldwater, E., *see* Bloomenthal, A. B., 1156
 Gottesman, M. M., *see* Morris, D. I., 329
 Graham, R. M., *see* Perez, D. M., 823
 Grant, F. J., *see* Kuestner, R. E., 246
 Greenberger, L. M., *see* Morris, D. I., 329
 Grever, M., *see* Lee, J.-S., 627
 Grimaldi, P. A., *see* Ibrahimi, A., 1070
 Grimm, S. W., Dyroff, M. C., Philpot, R. M., and Halpert, J. R. Catalytic selectivity and mechanism-based inactivation of stably expressed and hepatic cytochromes P450 2B4 and 2B5: implications of the cytochrome P450 2B5 polymorphism, 1090
 Grimsby, J., *see* Chen, K., 1226
 Gruntmeir, J. J., *see* Schattenberg, D. G., 346
 Guan, H.-C., *see* Asghari, V., 364
 Gudas, L. J., *see* Chen, M., 88
 Guengerich, F. P., *see* Yamazaki, H., 568
 Guillemare, E., Honore, E., De Wille, J., Fosset, M., Lazdunski, M., and Meisheri, K. Functional receptors in *Xenopus* oocytes for U-37883A, a novel ATP-sensitive K⁺ channel blocker: comparison with rat insulinoma cells, 139
 Guillouzo, A., *see* Abdel-Razzak, Z., 1100
 Gunduz, N. N., *see* Ritke, M. K., 58
 Guo, Z., *see* Yamazaki, H., 568
 Gusovsky, F., *see* Vanek, M., 832
 Gyenes, M., Wang, Q., Gibbs, T. T., and Farb, D. H. Phosphorylation factors control neurotransmitter and neuromodulator actions at the γ -aminobutyric acid type A receptor, 542
 Györke, S., *see* Dettbarn, C., 502

H

- Hacksell, U., *see* Malberg, Å., 299
 Hagen, F. S., *see* Kuestner, R. E., 246

- Hales, C. N., *see* Lee, K., 176
Hall, Z. W., *see* Yu, X.-M., 964
Halpert, J. R., *see* Grimm, S. W., 1090
Halpert, J. R., *see* Hasler, J. A., 338
Han, B., *see* Brady, K. D., 644
Han, C., *see* Minneman, K. P., 929
Hanley, M. R., *see* Sasakawa, N., 380
Harbon, S., *see* Khac, L. D., 485
Harden, T. K., *see* Filtz, T. M., 8
Hargreaves, A. C., Lummis, S. C. R., and Taylor, C. W. Ca²⁺ permeability of cloned and native 5-hydroxytryptamine type 3 receptors, 1120
Hargreaves, R. J., *see* Patel, S., 943
Harlow, G. R., *see* Hasler, J. A., 338
Harris, R. A., *see* Mihic, S. J., 851
Harrison, N. L., *see* Bloomenthal, A. B., 1156
Hasler, J. A., Harlow, G. R., Szklarz, G. D., John, G. H., Kedzie, K. M., Burnett, V. L., He, Y.-A., Kaminsky, L. S., and Halpert, J. R. Site-directed mutagenesis of putative substrate recognition sites in cytochrome P450 2B11: importance of amino acid residues 114, 290, and 363 for substrate specificity, 338
Hastings, G. A., *see* Buller, A. L., 858
Hawkins, L. D., *see* Vanek, M., 832
Hawkinson, J. E., Kimbrough, C. L., Belelli, D., Lambert, J. J., Purdy, R. H., and Lan, N. C. Correlation of neuroactive steroid modulation of [³⁵S]-butylbicyclopentylphosphorothionate and [³H]flunitrazepam binding and γ -aminobutyric acid_A receptor function, 977
Hayden, P. J., Free, K. E., and Chignell, C. F. Structure-activity relationships for the formation of secondary radicals and inhibition of keratinocyte proliferation by 9-anthrones, 186
He, Y.-A., *see* Hasler, J. A., 338
Heaslip, R. J., *see* Beavo, J. A., 399
Heer, S., *see* Ritke, M. K., 605
Helm, K. M., *see* Schattner, D. G., 346
Henry, E. C., Rucci, G., and Gasiewicz, T. A. Purification to homogeneity of the heteromeric DNA-binding form of the aryl hydrocarbon receptor from rat liver, 1022
Herrmann, F., *see* Ahlers, A., 1077
Herzer, T., *see* Busch, A. E., 750
Hindley, R. M., *see* Muzzin, P., 357
Holland, J. F., *see* Dorai, T., 437
Hollenberg, M. D., *see* Yang, S.-G., 256
Hollinger, S., *see* Minneman, K. P., 929
Honore, E., *see* Guillemare, E., 139
Hord, N. G., and Perdew, G. H. Physicochemical and immunocytochemical analysis of the aryl hydrocarbon receptor nuclear translocator: characterization of two monoclonal antibodies to the aryl hydrocarbon receptor nuclear translocator, 618
Hose, C., *see* Lee, J.-S., 627
Houssami, S., *see* Kuestner, R. E., 246
Howlett, A. C., *see* Pinto, J. C., 516
- I**
- Ibrahimi, A., Teboul, L., Gaillard, D., Amri, E.-Z., Ailhaud, G., Young, P., Cawthorne, M. A., and Grimaldi, P. A. Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells, 1070
Ichimura, M., *see* Nonaka, H., 817
Ichinose, I., *see* Ben-Baruch, N., 73
Ignarro, L. J., *see* Slusher, B. S., 115
Ingelman-Sundberg, M., *see* Johansson, I., 452
Inoue, H., *see* Koike, R., 599
Inoue, K., *see* Yamazaki, H., 568
Ionescu, P., *see* Mihic, S. J., 851
Irons, R. D., *see* Schattner, D. G., 346
Israel, Y., *see* Moncada, C., 786
Iversen, L. L., *see* Patel, S., 943
Iversen, S. D., *see* Patel, S., 943
Ivkovic, B., Bakthavachalam, V., Zhang, W., Parini, A., Diz, D., Bosch, S., Neumeyer, J. L., and Lanier, S. M. Development of a high-affinity radioiodinated ligand for identification of imidazole/guanidinium receptive sites (IGRS): intratissue distribution of IGRS in liver, forebrain, and kidney, 15
Izumi, F., *see* Tsutsui, M., 1041
Izumi, F., *see* Yanagihara, N., 423
- J**
- Jacquenmin-Sablon, A., *see* Khelifa, T., 323
Jahnsen, T., *see* Meinecke, M., 283
Jarchau, T., *see* Meinecke, M., 283
Jarvie, K. R., *see* Robinson, S. W., 352
Jastorff, B., *see* Schultz, C., 702
Jenkinson, S., Nahorski, S. R., and Challiss, R. A. J. Disruption by lithium of phosphatidylinositol-4,5-bisphosphate supply and inositol-1,4,5-trisphosphate generation in Chinese hamster ovary cells expressing human recombinant m₁ muscarinic receptors, 1138
Jensen, R. T., *see* Benya, R. V., 235, 495
Johansson, A. M., *see* Malmberg, Å., 299
Johansson, I., Oscarson, M., Yue, Q.-Y., Bertilsson, L., Sjöqvist, F., and Ingelman-Sundberg, M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation, 452
John, G. H., *see* Hasler, J. A., 338
Johns, D. G., *see* Ahluwalia, G. S., 1002
Johns, D. G., *see* Gao, W.-Y., 767
Johns, D. G., *see* Zhang, H., 1063
Johnson, M. R., *see* Pinto, J. C., 516
Jones, O. T. G., *see* O'Donnell, V. B., 778
Jordan, S. J., *see* Chamulitrat, W., 391
Joseph-Lilauzune, E., *see* Farges, R., 1160
Jovanovic, V., *see* Asghari, V., 364
Juchau, M. R., *see* Yang, H.-Y. L., 922
- K**
- Kallia-Raftopoulos, S., Kalpaxis, D. L., and Coutsoygeorgopoulos, C. New aspects of the kinetics of inhibition by lincomycin of peptide bond formation, 1009
Kalpaxis, D. L., *see* Kallia-Raftopoulos, S., 1009
Kaminsky, L. S., *see* Hasler, J. A., 338
Kaplowitz, N., *see* Lu, S. C., 578
Kase, H., *see* Koike, R., 599
Kase, H., *see* Nonaka, H., 817
Kass, R. S., *see* Bangalore, R., 660
Katayama, K., *see* Kuwada, M., 587
Katki, A. G., *see* Klecker, R. W., 1204
Kawai, T., *see* Kuwada, M., 587
Kawakami, Y., *see* Kuwada, M., 587
Kazanietz, M. G., Lewin, N. E., Gao, F., Pettit, G. R., and Blumberg, P. M. Binding of [26-³H]bryostatins 1 and analogs to calcium-dependent and calcium-independent protein kinase C isozymes, 374
Keaton, L. L., *see* Pou, S., 709
Kedzie, K. M., *see* Hasler, J. A., 338
Kedzie, K. M., *see* Regan, J. W., 213
Kemp, J. A., *see* Ebert, B., 957
Kemp, J. A., *see* Patel, S., 943
Kemp, J. A., *see* Priestley, T., 1191
Kempner, E. S., *see* Berger, S. P., 726
Kennedy, E., *see* Nieto, M., 406

- Khac, L. D., Naze, S., and Harbon, S. Endothelin receptor type A signals both the accumulation of inositol phosphates and the inhibition of cyclic AMP generation in rat myometrium: stimulation and desensitization, 485
- Kharbada, S., Emoto, Y., Kasaki, H., Saleem, A., and Kufe, D. 1- β -D-Arabinofuranosylcytosine activates serine/threonine protein kinases and *c-jun* gene expression in phorbol ester-resistant myeloid leukemia cells, 67
- Khélifa, T., Casabianca-Pignède, M.-R., René, B., and Jacquemin-Sablon, A. Expression of topoisomerases II α and β in Chinese hamster lung cells resistant to topoisomerase II inhibitors, 323
- Kieffer, B., *see* Simonin, F., 1015
- Kimbrough, C. L., *see* Hawkinson, J. E., 977
- Kimmel, H. L., *see* Barker, E. L., 799
- King, G. R., *see* Silvia, C. P., 51
- Kirkness, E. F., *see* Buller, A. L., 858
- Kisaki, H., *see* Kharbada, S., 67
- Klecker, R. W., Katki, A. G., and Collins, J. M. Toxicity, metabolism, DNA incorporation with lack of repair, and lactate production for 1-(2'-Fluoro-2'-deoxy- β -D-arabinofuranosyl)-5-iodouracil in U-937 and MOLT-4 cells, 1204
- Kobayashi, H., *see* Dorai, T., 437
- Koike, R., Miki, I., Otoshi, M., Totsuka, T., Inoue, H., Kase, H., Saito, I., and Miyasaka, N. Gold sodium thiomalate down-regulates intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression on vascular endothelial cells, 599
- Krasznai, Z., *see* Gáspár, R., Jr., 762
- Krause, J. E., *see* Sachais, B. S., 122
- Krogsgaard-Larsen, P., *see* Ebert, B., 957
- Kuestner, R. E., Elrod, R. D., Grant, F. J., Hagen, F. S., Kuijper, J. L., Matthewes, S. L., O'Hara, P. J., Sheppard, P. O., Stroop, S. D., Thompson, D. L., Whitmore, T. E., Findlay, D. M., Houssami, S., Sexton, P. M., and Moore, E. E. Cloning and characterization of an abundant subtype of the human calcitonin receptor, 246
- Kufe, D., *see* Kharbada, S., 67
- Kuhlenkamp, J., *see* Lu, S. C., 578
- Kuijper, J. L., *see* Kuestner, R. E., 246
- Kule, C., Ondrejickova, O., and Verner, K. Doxorubicin, daunorubicin, and mitoxantrone cytotoxicity in yeast, 1234
- Kumagaye, K. Y., *see* Kuwada, M., 587
- Kuo, C.-C., and Bean, B. P. Slow binding of phenytoin to inactivated sodium channels in rat hippocampal neurons, 716
- Kuroiwa, A., *see* Tsutsui, M., 1041
- Kursar, J. D., Nelson, D. L., Wainscott, D. B., and Baez, M. Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine_{2B} receptor, 227
- Kusui, T., *see* Benya, R. V., 235
- Kuwada, M., Teramoto, T., Kumagaye, K. Y., Nakajima, K., Watanabe, T., Kawai, T., Kawakami, Y., Niidome, T., Sawada, K., Nishizawa, Y., and Katayama, K. ω -Agatoxin-TK containing D-Serine at position 46, but not synthetic ω -[L-ser⁴⁶]agatoxin-TK, exerts blockade of P-type calcium channels in cerebellar Purkinje neurons, 587
- Kuzmenko, Y. S., *see* Tkachuk, V. A., 1129
- L**
- Lai, Y.-K., *see* Perng, M.-D., 612
- Laing, N., *see* Speicher, L. A., 866
- La Loggia, A. J., *see* Wigler, P. W., 563
- Lambert, J. J., *see* Hawkinson, J. E., 977
- Lamping, N., *see* Ahlers, A., 1077
- Lan, N. C., *see* Hawkinson, J. E., 977
- Lang, F., *see* Busch, A. E., 750
- Lanier, S. M., *see* Ivkovic, B., 15
- Lannes, B., *see* Simonin, F., 1015
- Lanzi, C., *see* Banfi, P., 896
- Larguier, R., *see* Nouet, S., 693
- Larsen, A. K., *see* Barret, J.-M., 431
- Laz, T. M., Forray, C., Smith, K. E., Bard, J. A., Vaysse, P. J.-J., Branchek, T. A., and Weinshank, R. L. The rat homologue of the bovine α_{1C} -adrenergic receptor shows the pharmacological properties of the classical α_{1A} subtype, 414
- Lazdunski, M., *see* Guillemare, E., 139
- Lazo, J. S., *see* Ritke, M. K., 605
- Lebreton, C., *see* Le Panse, R., 445
- Lee, J.-S., Paull, K., Alvarez, M., Hose, C., Monks, A., Grever, M., Fojo, A. T., and Bates, S. E. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen, 627
- Lee, K., Ozanne, S. E., Rowe, I. C. M., Hales, C. N., and Ashford, M. L. J. The effects of trypsin on ATP-sensitive potassium channel properties and sulfonylurea receptors in the CRI-G1 insulin-secreting cell line, 176
- Lee, Q. P., *see* Yang, H.-Y. L., 922
- Lee, T. H., *see* Silvia, C. P., 51
- Le Fur, G., *see* Farges, R., 1160
- Le Panse, R., Coulomb, B., Mitev, V., Bouchard, B., Lebreton, C., and Dubertret, L. Differential modulation of human fibroblast and keratinocyte growth by the protein kinase C inhibitor GF 109203X, 445
- Lewin, N. E., *see* Kazanietz, M. G., 374
- Li, Q., *see* Filtz, T. M., 8
- Li, Y.-M., *see* Blanton, M. P., 1048
- Liebmann, C., Bosse, R., and Escher, E. Discrimination between putative bradykinin B₂ receptor subtypes in guinea pig ileum smooth muscle membranes with selective, iodinated, bradykinin analogue, 949
- Lin, W. Q., Van Dyke, R. A., Marsh, H. M., and Trudell, J. R. Time course of 72-kilodalton heat shock protein induction and appearance of trifluoroacetyl adducts in livers of halothane-exposed rats, 639
- Lindon, J. C., *see* Anthony, M. L., 199
- Lindstrom, J., *see* Peng, X., 523
- Liu, Q.-Y., Dunlap, V., and Barker, J. L. γ -Aminobutyric acid type A receptor antagonists picrotoxin and bicuculline alter acetylcholine channel kinetics in cultured embryonic rat skeletal muscle, 1197
- Logothetis, D. E., *see* Castle, N. A., 1175
- Lohmann, S. M., *see* Meinecke, M., 283
- Lolait, S. J., *see* O'Carroll, A.-M., 291
- Lombard, C., *see* Nouet, S., 693
- Lu, S. C., Kuhlenkamp, J., Ge, J.-L., Sun, W.-M., and Kaplowitz, N. Specificity and directionality of thiol effects on sinusoidal glutathione transport in rat liver, 578
- Lumms, S. C. R., *see* Hargreaves, A. C., 1120
- Lyon, K. L., *see* Wigler, P. W., 563
- Lyon, T., *see* Wong, G., 1056
- M**
- Maayani, S., *see* Berg, K. A., 477
- Madan, A., Williams, T. D., and Faiman, M. D. Glutathione- and glutathione-S-transferase-dependent oxidative desulfuration of the thione xenobiotic diethyldithiocarbamate methyl ester, 1217
- Maggio, J. E., *see* Blanton, M. P., 1048
- Makino, I., *see* Makino, Y., 1084
- Makino, Y., Tanaka, H., and Makino, I. Paradoxical derepression of collagenase gene expression by the antirheumatic gold compound aurothiomalate, 1084
- Maksay, G. Thermodynamics of γ -aminobutyric acid type A receptor binding differentiate agonists from antagonists, 386
- Malik, N., *see* Perez, D. M., 823
- Malmberg, Å., Nordvall, G., Johansson, A. M., Mohell, N., and Hacksell, U. Molecular basis for binding of 2-aminotetralins to human dopamine D_{2A} and D₃ receptors, 299

- Marie, J., *see* Nouet, S., 693
 Marsh, H. M., *see* Lin, W. Q., 639
 Marshall, G. R., *see* Patel, S., 943
 Mash, D. C., *see* Ferrari-Dileo, G., 1028
 Maslanski, J. A., *see* Slusher, B. S., 115
 Mason, R. P., *see* Chamulitrat, W., 391
 Matassa, V. G., *see* Patel, S., 943
 Mathis, N., *see* Muzzin, P., 357
 Matthes, H., *see* Simonin, F., 1015
 Matthews, S. L., *see* Kuestner, R. E., 246
 Mayer, M. L., *see* Partin, K. M., 129
 McLane, M. W., *see* Slusher, B. S., 115
 McMahon, J., *see* Nitiss, J. L., 773
 McQuilkin, S. J., *see* Mihic, S. J., 851
 Meinecke, M., Geiger, J., Butt, E., Sandberg, M., Jahnsen, T., Chakraborty, T., Walter, U., Jarchau, T., and Lohmann, S. M. Human cyclic GMP-dependent protein kinase β overexpression increases phosphorylation of an endogenous focal contact-associated vasodilator-stimulated phosphoprotein without altering the thrombin-evoked calcium response, 283
 Meisheri, K., *see* Guillemare, E., 139
 Meyer, U. A., *see* de Moraes, S. M. F., 594
 Meyers, W. C., *see* Price, D. T., 221
 Micheletti, G., *see* Simonin, F., 1015
 Mihic, S. J., McQuilkin, S. J., Eger, E. I., II, Ionescu, P., and Harris, R. A. Potentiation of γ -aminobutyric acid type A receptor-mediated chloride currents by novel halogenated compounds correlates with their abilities to induce general anesthesia, 851
 Mihich, E., *see* Zaleskis, G., 901
 Miki, I., *see* Koike, R., 599
 Miles, M. F., Wilke, N., Elliot, M., Tanner, W., and Shah, S. Ethanol-responsive genes in neural cells include the 78-kilodalton glucose-regulated protein (GRP78) and 94-kilodalton glucose-regulated protein (GRP94) molecular chaperones, 873
 Miller, K. W., *see* Firestone, L. L., 508
 Milligan, G., *see* Shah, B. H., 1
 Mimura, M., *see* Yamazaki, H., 568
 Minneman, K. P., Theroux, T. L., Hollinger, S., Han, C., and Esbenshade, T. A. Selectivity of agonists for cloned α_1 -adrenergic receptor subtypes, 929
 Mitchelson, F., *see* Christopoulos, A., 105
 Mitev, V., *see* Le Panse, R., 445
 Mitsuya, H., *see* Ahluwalia, G. S., 1002
 Mitsuya, H., *see* Gao, W.-Y., 767
 Miyamoto, E., *see* Tsutsui, M., 1041
 Miyamoto, E., *see* Yanagihara, N., 423
 Miyasaka, N., *see* Koike, R., 599
 Mizumoto, K., Rothman, R. J., and Farber, J. L., Programmed cell death (apoptosis) of mouse fibroblasts is induced by the topoisomerase II inhibitor etoposide, 890
 Mlinar, B., and Enyeart, J. J. Identical inhibitory modulation of A-type potassium currents by dihydropyridine calcium channel agonists and antagonists, 743
 Mohell, N., *see* Malmberg, Å., 299
 Moncada, C., Torres, V., Varghese, G., Albano, E., and Israel, Y. Ethanol-derived immunoreactive species formed by free radical mechanisms, 786
 Monks, A., *see* Lee, J.-S., 627
 Monreal, J., *see* Díaz, R. S., 1210
 Moore, E. E., *see* Kuestner, R. E., 246
 Moore, W. C., *see* Slusher, B. S., 115
 Morain, P., Abraham, C., Portevin, B., and De Nanteuil, G. Biguanide derivatives: agonist pharmacology at 5-hydroxytryptamine type 3 receptors *in vitro*, 732
 Mori, A., *see* Nonaka, H., 817
 Morris, D. I., Greenberger, L. M., Bruggemann, E. P., Cardarelli, C., Gottesman, M. M., Pastan, I., and Seamon, K. B. Localization of the forskolin labeling sites to both halves of P-glycoprotein: similarity of the sites labeled by forskolin and prazosin, 329
 Mrozinski, J., *see* Benya, R. V., 495
 Mulcahy, R. T., Untawale, S., and Gipp, J. J. Transcriptional up-regulation of γ -glutamylcysteine synthetase gene expression in melphalan-resistant human prostate carcinoma cells, 909
 Murphy, T. J., *see* Nickenig, G., 653
 Muzzin, P., Boss, O., Mathis, N., Revelli, J.-P., Giacobino, J.-P., Willcocks, K., Badman, G. T., Cantello, B. C. C., Hindley, R. M., and Cawthorne, M. A. Characterization of a new, highly specific, β_3 -adrenergic receptor radioligand, [3 H]SB 206606, 357
- ## N
- Nahorski, S. R., *see* Jenkinson, S., 1138
 Nakajima, K., *see* Kuwada, M., 587
 Nakamura, K.-i., *see* Ushikubi, F., 808
 Nakamura, K., *see* de Moraes, S. M. F., 594
 Nappey, V., *see* Simonin, F., 1015
 Narumiya, S., *see* Ushikubi, F., 808
 Naze, S., *see* Khac, L. D., 485
 Neduvélil, J. G., *see* Patel, S., 943
 Nelson, D. L., *see* Kursar, J. D., 227
 Nelson, M. E., and Albuquerque, E. X. 9-Aminoacridines act at a site different from that for Mg^{2+} in blockade of the *N*-methyl-D-aspartate receptor channel, 151
 Neumeyer, J. L., *see* Ivkovic, B., 15
 Nicholas, R. A., *see* Filtz, T. M., 8
 Nicholson, J. K., *see* Anthony, M. L., 199
 Nickenig, G., and Murphy, T. J. Down-regulation by growth factors of vascular smooth muscle angiotensin receptor gene expression, 653
 Nieto, M., Kennedy, E., Goldstein, D., and Brown, J. H. Rapid heterologous desensitization of muscarinic and thrombin receptor-mediated phospholipase D activation, 406
 Niidome, T., *see* Kuwada, M., 587
 Nishizawa, Y., *see* Kuwada, M., 587
 Nitiss, J. L., Vilalta, P. M., Wu, H., and McMahon, J. Mutations in the *gyrB* domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine, 773
 Nonaka, H., Mori, A., Ichimura, M., Shindou, T., Yanagawa, K., Shimada, J., and Kase, H. Binding of [3 H]KF17837S, a selective adenosine A_2 receptor antagonist, to rat brain membranes, 817
 Nordvall, G., *see* Malmberg, Å., 299
 Norris, T. E., *see* Slusher, B. S., 115
 Nouet, S., Dodey, P., Renaut, P., Marie, J., Pruneau, D., Larguier, R., Lombard, C., and Bonnafous, J.-C. Properties of [3 H]LF 7-0156, a new nonpeptide antagonist radioligand for the type 1 angiotensin II receptor, 693
- ## O
- O'Carroll, A.-M., Raynor, K., Lolait, S. J., and Reisine, T. Characterization of cloned human somatostatin receptor SSTR5, 291
 O'Donnell, V. B., Smith, G. C. M., and Jones, O. T. G. Involvement of phenyl radicals in iodonium compound inhibition of flavoenzymes, 778
 Ohara, K., *see* Asghari, V., 364
 O'Hara, P. J., *see* Kuestner, R. E., 246
 Ohnuma, T., *see* Dorai, T., 437
 Ohta, Y., *see* Yanagihara, N., 423
 Ondrejickova, O., *see* Kule, C., 1234
 Osawa, S., and Weiss, E. R. The carboxyl terminus of bovine rhodopsin is not required for G protein activation, 1036
 Oscarson, M., *see* Johansson, I., 452
 Otsoshi, M., *see* Koike, R., 599
 Ozanne, S. E., *see* Lee, K., 176

P

- Palade, P., *see* Dettbarn, C., 502
 Palen, D., *see* Poland, A., 915
 Panyi, G., *see* Gáspár, R., Jr., 762
 Parini, A., *see* Ivkovic, B., 15
 Park-Chung, M., Wu, F.-S., and Farb, D. H. 3 α -Hydroxy-5 β -pregnan-20-one sulfate: a negative modulator of the NMDA-induced current in cultured neurons, 146
 Partin, K. M., Patneau, D. K., and Mayer, M. L. Cyclothiazide differentially modulates desensitization of α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor splice variants, 129
 Pastan, I., *see* Morris, D. I., 329
 Patel, S., Smith, A. J., Champman, K. L., Fletcher, A. E., Kemp, J. A., Marshall, G. R., Hargreaves, R. J., Ryecroft, W., Iversen, L. L., Iversen, S. D., Baker, R., Showell, G. A., Bourrain, S., Neduvellil, J. G., Matassa, V. G., and Freedman, S. B. Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity *in vitro* and high potency *in vivo*, 943
 Patneau, D. K., *see* Partin, K. M., 129
 Patterson, F. K., *see* Wigler, P. W., 563
 Paudice, P., *see* Gemignani, A., 558
 Paul, S., *see* Berger, S. P., 726
 Paull, K., *see* Lee, J.-S., 627
 Peng, X., Gerzanich, V., Anand, R., Whiting, P. J., and Lindstrom, J. Nicotine-induced increase in neuronal nicotinic receptors results from a decrease in the rate of receptor turnover, 523
 Pepperl, D. J., *see* Regan, J. W., 213
 Perdeu, G. H., *see* Hord, N. G., 618
 Perez, D. M., Piascik, M. T., Malik, N., Gaivin, R., and Graham, R. M. Cloning, expression, and tissue distribution of the rat homolog of the bovine α_{1C} -adrenergic receptor provide evidence for its classification as the α_{1A} subtype, 823
 Perez, D. M., *see* Piascik, M. T., 30
 Perng, M.-D., Cheng, T.-J., Chen, C.-M., and Lai, Y.-K. Induction of aggregation and augmentation of protein kinase-mediated phosphorylation of purified vimentin intermediate filaments by withanolide A, 612
 Persmark, M., *see* Yamazaki, H., 568
 Petronis, A., *see* Asghari, V., 364
 Pettit, G. R., *see* Kazanietz, M. G., 374
 Pettit, G. R., *see* Szallasi, Z., 840
 Philpot, R. M., *see* Grimm, S. W., 1090
 Piascik, M. T., *see* Perez, D. M., 823
 Piascik, M. T., Smith, M. S., Soltis, E. E., and Perez, D. M. Identification of the mRNA for the novel α_{1D} -adrenoceptor and two other α_1 -adrenoceptors in vascular smooth muscle, 30
 Pierce, K. L., *see* Regan, J. W., 213
 Pieri, C., *see* Gáspár, R., Jr., 762
 Pinto, J. C., Potié, F., Rice, K. C., Boring, D., Johnson, M. R., Evans, D. M., Wilken, G. H., Cantrell, C. H., and Howlett, A. C. Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid, 516
 Pinto, W., and Battaglia, G. Comparative recovery kinetics of 5-hydroxytryptamine 1A, 1B, and 2A receptor subtypes in rat cortex after receptor inactivation: evidence for differences in receptor production and degradation, 1111
 Poland, A., Palen, D., and Glover, E. Analysis of the four alleles of the murine aryl hydrocarbon receptor, 915
 Pollock, K. M., *see* Couceyro, P., 667
 Portevin, B., *see* Morain, P., 732
 Potié, K. C., *see* Pinto, J. C., 516
 Pou, S., Anderson, D. E., Surichamorn, W., Keaton, L. L., and Tod, M. L. Biological studies of a nitroso compound that releases nitric oxide upon illumination, 709
 Pradhan, T., *see* Benya, R. V., 235

- Price, D. T., Chari, R. S., Berkowitz, D. E., Meyers, W. C., and Schwinn, D. A. Expression of α_1 -adrenergic receptor subtype mRNA in rat tissues and human SK-N-MC neuronal cells: implications for α_1 -adrenergic receptor subtype classification, 221
 Priestley, T., and Kemp, J. A. Kinetic study of the interactions between the glutamate and glycine recognition sites on the N-methyl-D-aspartic acid receptor complex, 1191
 Pritchett, D. B., *see* Bloomenthal, A. B., 1156
 Pruneau, D., *see* Nouet, S., 693
 Purdy, R. H., *see* Hawkinson, J. E., 977

R

- Raber, G., *see* Busch, A. E., 750
 Racagni, G., *see* Volterra, A., 986
 Raiteri, M., *see* Gemignani, A., 558
 Rane, S. G., *see* Twitchell, W. A., 793
 Raully, I., *see* Vidal, C., 97
 Raynor, K., *see* O'Carroll, A.-M., 291
 Reddy, M. S., *see* Wigler, P. W., 563
 Regan, J. W., Bailey, T. J., Pepperl, D. J., Pierce, K. L., Bogardus, A. M., Donello, J. E., Fairbairn, C. E., Kedzie, K. M., Woodward, D. F., and Gil, D. W. Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP₂ subtype, 213
 Reinhold, W. C., *see* Ben-Baruch, N., 73
 Reisine, T., *see* O'Carroll, A.-M., 291
 Renaut, P., *see* Nouet, S., 693
 René, B., *see* Khélifa, T., 323
 Resink, T. J., *see* Tkachuk, V. A., 1129
 Rettie, A. E., *see* Yang, H.-Y. L., 922
 Revelli, J.-P., *see* Muzzin, P., 357
 Rice, K. C., *see* Pinto, J. C., 516
 Richelson, E., *see* Yamada, M., 470
 Ritke, M. K., Allan, W. P., Fattman, C., Gunduz, N. N., and Yalowich, J. C. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells, 58
 Ritke, M. K., Rusnak, J. M., Lazo, J. S., Allan, W. P., Dive, C., Heer, S., and Yalowich, J. C. Differential induction of etoposide-mediated apoptosis in human leukemia HL-60 and K562 cells, 605
 Robbins, J. D., *see* Speicher, L. A., 866
 Robinson, S. W., Jarvie, K. R., and Caron, M. G. High affinity agonist binding to the dopamine D₃ receptor: chimeric receptors delineate a role for intracellular domains, 352
 Rogers, N. E., *see* Slusher, B. S., 115
 Rooney, A., *see* Simonson, M. S., 41
 Ross, D., *see* Schattenberg, D. G., 346
 Rothman, R. J., *see* Mizumoto, K., 890
 Rowe, I. C. M., *see* Lee, K., 176
 Rucci, G., *see* Henry, E. C., 1022
 Rusnak, J. M., *see* Ritke, M. K., 605
 Rust, G., *see* Cachelin, A. B., 1168
 Rutledge, A., *see* Bangalore, R., 660
 Ryecroft, W., *see* Patel, S., 943

S

- Sachais, B. S., and Krause, J. E. Both extracellular and transmembrane residues contribute to the species selectivity of the neurokinin-1 receptor antagonist WIN 51708, 122
 Safa, A. R., *see* Benchekroun, M. N., 677
 Sailstad, C., *see* Berg, K. A., 477
 Saint-Laurent, N., *see* Vidal, C., 97
 Saito, I., *see* Koike, R., 599
 Saleem, A., *see* Kharbanda, S., 67
 Salles, B., *see* Barret, J.-M., 431
 Saltzman, A., *see* Berg, K. A., 477

- Sánchez-Margalet, V., Valle, M., and Goberna, R. Receptors for pancreastatin in rat liver membranes: molecular identification and characterization by covalent cross-linking, 24
- Sandberg, M., *see* Meinecke, M., 283
- Sanders-Bush, E., *see* Westphal, R. S., 937
- Sasakawa, N., Ferguson, J. E., Sharif, M., and Hanley, M. R. Attenuation of agonist-induced desensitization of rat substance P receptor by microinjection of inositol Pentakis- and hexakisphosphates in *Xenopus laevis* oocytes, 380
- Sawada, K., *see* Kuwada, M., 587
- Scammell, J. G., *see* Thompson, M. E., 880
- Schattenberg, D. G., Stillman, W. S., Gruntmeir, J. J., Helm, K. M., Irons, R. D., and Ross, D. Peroxidase activity in murine and human hematopoietic progenitor cells: potential relevance to benzene-induced toxicity, 346
- Schmidt, F., *see* Busch, A. E., 750
- Schneider, E., *see* Benchekroun, M. N., 677
- Schoots, O., *see* Asghari, V., 364
- Schultz, C., Vajanaphanich, M., Genieser, H.-G., Jastorff, B., Barrett, K. E., and Tsien, R. Y. Membrane-permeant derivatives of cyclic AMP optimized for high potency, prolonged activity, or rapid reversibility, 702
- Schwinn, D. A., *see* Price, D. T., 221
- Scott-Burden, T., Elizondo, E., Ge, T., Boulanger, C. M., and Vanhoutte, P. M. Simultaneous activation of adenylyl cyclase and protein kinase C induces production of nitric oxide by vascular smooth muscle cells, 274
- Seamon, K. B., *see* Morris, D. I., 329
- Seamon, K. B., *see* Speicher, L. A., 866
- Sexton, P. M., *see* Kuestner, R. E., 246
- Shah, B. H., and Milligan, G. The gonadotrophin-releasing hormone receptor of α T3-1 pituitary cells regulates cellular levels of both of the phosphoinositidase C-linked G proteins, $G_{q\alpha}$ and $G_{11\alpha}$, equally, 1
- Shah, S., *see* Miles, M. F., 873
- Sharif, M., *see* Sasakawa, N., 380
- Shaw, P. M., Weiss, M. C., and Adesnik, M. Hepatocyte nuclear factor 3 is a major determinant of *CYP2C6* promoter activity in hepatoma cells, 79
- Sheppard, P. O., *see* Kuestner, R. E., 246
- Shih, J. C., *see* Chen, K., 1226
- Shimada, J., *see* Nonaka, H., 817
- Shimada, T., *see* Yamazaki, H., 568
- Shindou, T., *see* Nonaka, H., 817
- Shirasaka, T., *see* Ahluwalia, G. S., 1002
- Shire, D., *see* Farges, R., 1160
- Showell, G. A., *see* Patel, S., 943
- Silvia, C. P., King, G. R., Lee, T. H., Xue, Z.-Y., Caron, M. G., and Ellinwood, E. H. Intranigral administration of D_2 dopamine receptor antisense oligodeoxynucleotides establishes a role for nigrostriatal D_2 autoreceptors in the motor actions of cocaine, 51
- Simonin, F., Befort, K., Gavériaux-Ruff, C., Matthes, H., Nappey, V., Lannes, B., Micheletti, G., and Kieffer, B. The human δ -opioid receptor: genomic organization, cDNA cloning, functional expression, and distribution in human brain, 1015
- Simonson, M. S., and Rooney, A. Characterization of endothelin receptors in mesangial cells: evidence for two functionally distinct endothelin binding sites, 41
- Sinha, B. K., *see* Benchekroun, M. N., 677
- Sjöqvist, F., *see* Johansson, I., 452
- Skolnick, P., *see* Wong, G., 1056
- Slusher, B. S., Zacco, A. E., Maslanski, J. A., Norris, T. E., McLane, M. W., Moore, W. C., Rogers, N. E., and Ignarro, L. J. The cloned neurotensin receptor mediates cyclic GMP formation when co-expressed with nitric oxide synthase cDNA, 115
- Smith, A. J., *see* Patel, S., 943
- Smith, C. B., *see* Szallasi, Z., 840
- Smith, G. C. M., *see* O'Donnell, V. B., 778
- Smith, K. E., *see* Laz, T. M., 414
- Smith, M. S., *see* Piascik, M. T., 30
- Soltis, E. E., *see* Piascik, M. T., 30
- Sott, C., *see* Ahlers, A., 1077
- Speicher, L. A., Laing, N., Barone, L. R., Robbins, J. D., Seamon, K. B., and Tew, K. D. Interaction of an estramustine photoaffinity analogue with cytoskeletal proteins in prostate carcinoma cells, 866
- Sreenath, A., *see* Zhang, H., 1063
- Stambolsky, D. V., *see* Tkachuk, V. A., 1129
- Stillman, W. S., *see* Schattenberg, D. G., 346
- Stimson, E. R., *see* Blanton, M. P., 1048
- Stowe, E. E., *see* Zhang, H., 1063
- Strada, S. J., *see* Thompson, M. E., 880
- Stroop, S. D., *see* Kuestner, R. E., 246
- Sun, W.-M., *see* Lu, S. C., 578
- Surichamorn, W., *see* Pou, S., 709
- Susini, C., *see* Vidal, C., 97
- Sweatman, B. C., *see* Anthony, M. L., 199
- Szallasi, Z., Denning, M. F., Smith, C. B., Dlugosz, A. A., Yuspa, S. H., Pettit, G. R., and Blumberg, P. M. Bryostatins protect protein kinase C- δ from down-regulation in mouse keratinocytes in parallel with its inhibition of phorbol ester-induced differentiation, 840
- Szklarz, G. D., *see* Hasler, J. A., 338

T

- Tanaka, H., *see* Makino, Y., 1084
- Tanner, W., *see* Miles, M. F., 873
- Tashjian, A. H., Jr., *see* Brady, K. D., 644
- Taylor, C. W., *see* Hargreaves, A. C., 1120
- Teboul, L., *see* Ibrahim, A., 1070
- Teramoto, T., *see* Kuwada, M., 587
- Tew, K. D., *see* Speicher, L. A., 866
- Theroux, T. L., *see* Minneman, K. P., 929
- Thompson, D. L., *see* Kuestner, R. E., 246
- Thompson, M. E., Valentine, D. L., Strada, S. J., Wagner, J. A., and Scammell, J. G. Transcriptional regulation of secretogranin II and chromogranin B by cyclic AMP in a rat pheochromocytoma cell line, 880
- Thornalley, M., *see* Bailly, C., 313
- Tkachuk, V. A., Kuzmenko, Y. S., Resink, T. J., Stambolsky, D. V., and Bochkov, V. N. Atypical low density lipoprotein binding site that may mediate lipoprotein-induced signal transduction, 1129
- Tod, M. L., *see* Pou, S., 709
- Torres, V., *see* Moncada, C., 786
- Totsuka, T., *see* Koike, R., 599
- Townsend, A. J., *see* Benchekroun, M. N., 677
- Toyohira, Y., *see* Yanagihara, N., 423
- Trepel, J. B., *see* Ben-Baruch, N., 73
- Tricarico, D., and Camerino, D. C. ATP-sensitive K^+ channels of skeletal muscle fibers from young adult and aged rats: possible involvement of thiol-dependent redox mechanisms in the age-related modifications of their biophysical and pharmacological properties, 754
- Triggle, D. J., *see* Bangalore, R., 660
- Trotti, D., *see* Volterra, A., 986
- Trudell, J. R., *see* Lin, W. Q., 639
- Tsien, R. Y., *see* Schultz, C., 702
- Tsutsui, M., *see* Yanagihara, N., 423
- Tsutsui, M., Yanagihara, N., Miyamoto, E., Kuroiwa, A., and Izumi, F. Correlation of activation of Ca^{2+} /calmodulin-dependent protein kinase II with catecholamine secretion and tyrosine hydroxylase activation in cultured bovine adrenal medullary cells, 1041
- Twitchell, W. A., and Rane, S. G. Nucleotide independent modulation of Ca^{2+} -dependent K^+ channel current by a μ -type opioid receptor, 793

U

- Untawale, S., *see* Mulcahy, R. T., 909
 Ushikubi, F., Nakamura, K.-i., and Narumiya, S. Functional reconstitution of platelet thromboxane A₂ receptors with purified G_q and G_{i2} in phospholipid vesicles, 808

V

- Vajanaphanich, M., *see* Schultz, C., 702
 Valentine, D. L., *see* Thompson, M. E., 880
 Valle, M., *see* Sánchez-Margalet, V., 24
 Van Dyke, R. A., *see* Lin, W. Q., 639
 Vanek, M., Hawkins, L. D., and Gusovsky, F. Coupling of the C5a receptor to G_i in U-937 cells and in cells transfected with C5a receptor cDNA, 832
 Vanhoutte, P. M., *see* Scott-Burden, T., 274
 Van Kats, S., *see* Asghari, V., 364
 Van Tol, H. H. M., *see* Asghari, V., 364
 Varghese, G., *see* Moncada, C., 786
 Vaysse, N., *see* Vidal, C., 97
 Vaysse, P. J.-J., *see* Laz, T. M., 414
 Vereb, G., *see* Gáspár, R., Jr., 762
 Verner, K., *see* Kule, C., 1234
 Verstovsek, S., *see* Zaleskis, G., 901
 Vidal, A. M., *see* Dilger, J. P., 169
 Vidal, C., Raully, I., Zeggari, M., Delesque, N., Esteve, J.-P., Saint-Laurent, N., Vaysse, N., and Susini, C. Up-regulation of somatostatin receptors by epidermal growth factor and gastrin in pancreatic cancer cells, 97
 Vilalta, P. M., *see* Nitiss, J. L., 773
 Volterra, A., Trotti, D., and Racagni, G. Glutamate uptake is inhibited by arachidonic acid and oxygen radicals via two distinct and additive mechanisms, 986

W

- Waelbroeck, M. Identification of drugs competing with *d*-tubocurarine for an allosteric site on cardiac muscarinic receptors, 685
 Waelbroeck, M., *see* Ferrari-Dileo, G., 1028
 Wafford, K. A., *see* Ebert, B., 957
 Wagner, C. A., *see* Busch, A. E., 750
 Wagner, J. A., *see* Thompson, M. E., 880
 Wainscott, D. B., *see* Kursar, J. D., 227
 Waldegger, S., *see* Busch, A. E., 750
 Walter, U., *see* Meinecke, M., 283
 Wang, G. K., *see* Castle, N. A., 1175
 Wang, Q., *see* Gyenes, M., 542
 Waring, M. J., *see* Bailly, C., 313
 Watanabe, T., *see* Kuwada, M., 587
 Watson, M. A., *see* Yamada, M., 470
 Watson, S. P., *see* Barr, A. J., 266
 Weaver, W. R., Wolf, K. M., and Chiappinelli, V. A. Functional heterogeneity of nicotinic receptors in the avian lateral spiriform nucleus detected with trimethaphan, 993
 Weinshank, R. L., *see* Laz, T. M., 414
 Weiss, E. R., *see* Osawa, S., 1036
 Weiss, M. C., *see* Shaw, P. M., 79
 Westphal, R. S., and Sanders-Bush, E. Reciprocal binding properties of 5-hydroxytryptamine type 2C receptor agonists and inverse agonists, 937
 White, M. M., *see* Aylwin, M. L., 1149
 Whiting, P. J., *see* Ebert, B., 957
 Whiting, P. J., *see* Peng, X., 523
 Whitmore, T. E., *see* Kuestner, R. E., 246
 Wigler, P. W., Lyon, K. L., Patterson, F. K., La Loggia, A. J., Diaz-Araújo, H., Reddy, M. S., and Cook, J. M. Epoxide metabolite of

- quinine and inhibition of the multidrug resistance pump in human leukemic lymphoblasts, 563
 Wilke, N., *see* Miles, M. F., 873
 Wilken, G. H., *see* Pinto, J. C., 516
 Wilkinson, G. R., *see* de Moraes, S. M. F., 594
 Willcocks, K., *see* Muzzin, P., 357
 Williams, K. Mechanisms influencing stimulatory effects of spermine at recombinant *N*-methyl-D-aspartate receptors, 161
 Williams, K. Subunit-specific potentiation of recombinant *N*-methyl-D-aspartate receptors by histamine, 531
 Williams, T. D., *see* Madan, A., 1217
 Wolf, K. M., *see* Weaver, W. R., 993
 Wong, G., Lyon, T., and Skolnick, P. Chronic exposure to benzodiazepine receptor ligands uncouples the γ -aminobutyric acid type A receptor in WSS-1 cells, 1056
 Wong, N. C., *see* Yang, S.-G., 256
 Woodward, D. F., *see* Regan, J. W., 213
 Wu, F.-S., *see* Park-Chung, M., 146
 Wu, H.-F., *see* Chen, K., 1226
 Wu, H., *see* Nitiss, J. L., 773

X

- Xue, Z.-Y., *see* Silvia, C. P., 51

Y

- Yalowich, J. C., *see* Ritke, M. K., 58, 605
 Yamada, M., *see* Yamada, M., 470
 Yamada, M., Yamada, M., Watson, M. A., and Richelson, E. Deletion mutation in the putative third intracellular loop of the rat neurotensin receptor abolishes polyphosphoinositide hydrolysis but not cyclic AMP formation in CHO-K1 cells, 470
 Yamamoto, H., *see* Yanagihara, N., 423
 Yamazaki, H., Guo, Z., Persmark, M., Mimura, M., Inoue, K., Guengerich, F. P., and Shimada, T. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes, 568
 Yanagawa, K., *see* Nonaka, H., 817
 Yanagihara, N., *see* Tsutsui, M., 1041
 Yanagihara, N., Toyohira, Y., Yamamoto, H., Ohta, Y., Tsutsui, M., Miyamoto, E., and Izumi, F. Occurrence and activation of Ca²⁺/calmodulin-dependent protein kinase II and its endogenous substrates in bovine adrenal medullary cells, 423
 Yang, H.-Y. L., Lee, Q. P., Rettie, A. E., and Juchau, M. R. Functional cytochrome P4503A isoforms in human embryonic tissues: expression during organogenesis, 922
 Yang, S.-G., Ahmad, S., Wong, N. C., and Hollenberg, M. D. Ligand binding characterization and molecular analysis of distinct epidermal growth factor-urogastrone receptors in cultured smooth muscle and epithelial cells from guinea pig intestine, 256
 Yool, A. J. Block of the inactivating potassium channel by clofilium and hydroxylamine depends on the sequence of the pore region, 970
 Young, P., *see* Ibrahim, A., 1070
 Ypey, D. L., *see* Gáspár, R., Jr., 762
 Yu, X.-M., and Hall, Z. W. Amino- and carboxyl-terminal domains specify the identity of the δ subunit in assembly of the mouse muscle nicotinic acetylcholine receptor, 964
 Yue, Q.-Y., *see* Johansson, I., 452
 Yuspa, S. H., *see* Szallasi, Z., 840

Z

- Zacco, A. E., *see* Slusher, B. S., 115
 Zajac-Kaye, M., *see* Ben-Baruch, N., 73

- Zaleskis, G., Berleth, E., Verstovsek, S., Ehrke, M. J., and Mihich, E. Doxorubicin-induced DNA degradation in murine thymocytes, 901
- Zeggari, M., *see* Vidal, C., 97
- Zhan, Q., *see* Zhang, H., 1063
- Zhang, H., Cooney, D. A., Sreenath, A., Zhan, Q., Agbaria, R., Stowe, E. E., Fornace, A. J., Jr., and Johns, D. G. Quantitation of mitochondrial DNA in human lymphoblasts by a competitive polymerase chain reaction method: application to the study of inhibitors of mitochondrial DNA content, 1063
- Zhang, W., *see* Ivkovic, B., 15
- Zhu, X., Gilbert, S., Birnbaumer, M., and Birnbaumer, L. Dual signaling potential is common among G_s-coupled receptors and dependent on receptor density, 460

SUBJECT INDEX FOR VOLUME 46

A

- Acetylcholine receptor
 anesthetic-induced desensitization of, lipid disordering and (*Torpedo*), 508
 mutant, gating properties of (*Xenopus*), 1149
 nicotinic
 GABA receptor antagonist block of (rat), 1197
 heterogeneity of, in lateral spiriform nucleus (avian), 993
 muscle, subunit domain assembly in (mouse), 964
 substance P photoaffinity labeling of (*Torpedo*), 1048
 tubocurarine and (rat), 1168
 up-regulation of (mouse), 523
 Acetylcholine receptor channel, general anesthetic and QX-222 interactions in (BC3H-1 cells), 169
 Activator protein-1, striatal and cerebellar, cocaine and (rat), 667
 Adenosine monophosphate, cyclic
 generation of, endothelin receptor and, in myometrium (rat), 485
 GRP receptor-stimulated increases in (mouse), 235
 membrane-permeant derivatives of (human), 702
 secretogranin II and chromogranin B regulation by, in pheochromocytoma (rat), 880
 Adenosine triphosphate, potassium channel sensitive to blockers of, U-37883A as (*Xenopus*), 139
 in skeletal muscle fiber, aging and (rat), 754
 trypsin and (rat), 176
 Adenyl cyclase, nitric oxide production and (rat), 274
 Adhesion molecule, expression of, gold sodium thiomalate and (human), 599
 Adrenal medulla
 Ca²⁺/calmodulin-dependent kinase activation in (bovine), 1041
 calmodulin kinase and endogenous substrates in (bovine), 423
 α_1 -Adrenergic receptor
 agonist selectivity for (human), 929
 bovine, rat homolog of, 823
 cloning of (rat), 414, 823
 in SK-N-MC cells (human), 221
 β -Adrenergic receptor radioligand, [³H]SB 206606 as (hamster), 357
 α_1 -Adrenoceptor, in vascular smooth muscle (rat), 30
 Agatoxin-TK, calcium channel blockade and (rat), 587
 Aging, and skeletal muscle fiber ATP-sensitive potassium channels (rat), 754
 Aldehyde dehydrogenase
 cytosolic and mitochondrial, in retinaldehyde conversion (mouse), 88
 daunorubicin-binding protein as, in liver (mouse), 896
 Allosteric binding, to cardiac muscarinic receptors (rat), 685
 α -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, splice variants of, cyclothiazide and (*Xenopus*), 129
 Aminoacridine, NMDA receptor channel blockade by, Mg²⁺ and (rat), 151
 γ -Aminobutyric acid receptor
 antagonists to, embryonic nicotinic acetylcholine receptor block by (rat), 1197
 benzodiazepine and (WSS-1 cells), 1056
 binding of, thermodynamics of (rat), 386
 glycosylation of (human), 858
 halogenated anesthetic potentiation by (*Xenopus*), 851
 molecular pharmacology of (human), 957
 neuroactive steroid modulation of (rat), 977

- neuropeptide release and (rat), 558
 phosphorylation-dependent modulation of (chick), 542
 γ -Aminobutyric acid transporter, neuronal, in LLC-PK₁ cells, 550
 Aminopyridine, potassium channel inactivation and (rat), 1175
 2-Aminotetralin, binding of, to dopamine receptors (human), 299
 AMPA, *see* α -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
 Amsacrine, resistance to, topoisomerase II mutations and (yeast), 773
 Anesthetic
 acetylcholine receptor desensitization by, lipid disordering and (*Torpedo*), 508
 halogenated, GABA receptor currents and (*Xenopus*), 851
 Angiotensin I receptor, growth factors and, in vascular smooth muscle (rat), 653
 Angiotensin II receptor, nonpeptide radioligand for (rabbit), 693
 Ansamycin antibiotics, breast cancer cell resistance to (human), 677
 Anthracycline, cytotoxicity analysis of (yeast), 1234
 9-Anthrone radicals, structure-activity relationships and (human), 186
 Apoptosis
 by doxorubicin, in thymocyte (mouse), 901
 by etoposide
 in fibroblasts (mouse), 890
 in leukemia cells (human), 605
 Arabinofuranosylcytosine, protein kinase C activation and *c-jun* expression activated by, in leukemia cells (human), 67
 Arachidonic acid, glutamate uptake and (rat), 986
 Arachidonylamides, cannabinoid pharmacology of (rat), 516
 Aryl hydrocarbon receptor
 alleles of (mouse), 915
 DNA-binding form of, in liver (rat), 1022
 Aryl hydrocarbon receptor nuclear translocator, monoclonal antibodies to (human), 618
 Astrocytoma cell, phospholipase C activation by neurokinin receptor in, protein kinase C and (human), 266
 ATP, *see* Adenosine triphosphate
 Aurothiomalate, collagenase gene expression and (human), 1084

B

- Benzene, toxicity from, peroxidase activity and (human and mouse), 346
 Benzodiazepine, GABA receptor and (WSS-1 cells), 1056
 Benzodiazepine receptor, peripheral, mutagenesis of (human), 1160
 Bicuculline, embryonic acetylcholine receptor block by (rat), 1197
 Biguanine derivatives, at hydroxytryptamine receptors (rat), 732
 Bradykinin B₂ receptor subtypes, iodinated bradykinin discrimination among (guinea pig), 949
 Brain
 hydroxytryptamine 1 and 2 receptor subtypes in, kinetics of (rat), 1111
 [³H]KF17837S binding to (rat), 817
 δ -opioid receptor in (human), 1015
 Breast cancer cell, ansamycin antibiotic resistance in (human), 677
 Bretium tosylate, voltage-gated potassium channel block by (human), 762
 Bryostatins, binding of, to protein kinase C isozymes (Sf9 insect), 374
 Bufuralol, hydroxylation of, by cytochrome P450 2D6 and 1A2, in liver (human), 568

- Butamidine drugs, sequence-selective binding of, to DNA (human), 313
 Butanol, QX-222 interactions with, in acetylcholine receptor channel (BC3H-1 cells), 169
 Butylbicyclophosphorothionate, binding of, neuroactive steroid modulation of (rat), 977
 Byrostatin, protein kinase C regulation by (mouse), 840

C

- C5a receptor, coupling of, to protein G (human), 832
 Ca²⁺/calmodulin-dependent kinase, activation of, in adrenal medulla (bovine), 1041
 Calcitonin receptor, subtypes of (human), 246
 Calcium, release of, from muscle ryanodine receptors (rabbit), 502
 Calcium channel
 blockade of, agatoxin-TK and (rat), 587
 L-type, dihydropyridine binding domain of (guinea pig), 660
 Calcium permeability, of hydroxytryptamine 3 receptor (human), 1120
 Calmodulin kinase, and endogenous substrates, in adrenal medulla (bovine), 423
 Cannabinoid pharmacology, of arachidonylamides (rat), 516
 Cardiac muscarinic receptor, allosteric binding to (rat), 685
 Catecholamine, secretion of, Ca²⁺/calmodulin-dependent kinase activation and, in adrenal medulla (bovine), 1041
 Cerebellar neuron, calcium channel blockade in, agatoxin-TK and (rat), 587
 Cerebellum, activator protein-1 in, cocaine and (rat), 667
 cGMP, *see* Guanosine monophosphate, cyclic
 Chloride channel blocker, potassium current regulation by (human), 750
 Chloride/hydroxyl ion exchange, through myelin lipid bilayers, thallium and (human), 1210
 Cholecystokinin, release of, GABA receptor and (rat), 558
 Cholecystokinin-B antagonist, L-740,093 as (guinea pig), 943
 Chromogranin B, cyclic AMP regulation of, in pheochromocytoma (rat), 880
 Cisplatin, cellular resistance to, topoisomerase II in (mouse), 431
 c-jun expression, arabinofuranosylcytosine and, in leukemia cell (human), 67
 Clofilium, potassium channel block by (*Xenopus*), 970
 c-myc expression, in suramin-treated cell (human), 73
 Cocaine, striatal and cerebellar activator protein systems and (rat), 667
 Cocaine motor action, dopamine autoreceptors and (rat), 51
 Collagenase gene, expression of, aurothiomalate and (human), 1084
 Cyclothiazide, AMPA receptor splice variants and (*Xenopus*), 129
 CYP2D6 locus, Chinese (human), 452
 Cytochrome P450
 03A gene, in organogenesis (human), 922
 2B4 and 2B5, catalytic differences in (rabbit), 1090
 2B11, substrate recognition sites in (dog, mouse, rabbit, and rat), 338
 2C6, in hepatoma cell, transcriptional regulation of (rat), 79
 2D, Chinese (human), 452
 2D6 and 1A2, bufuralol hydroxylation by, in liver (human), 568
 polycyclic aromatic hydrocarbon induction of, cytokines and (human), 1100
 Cytoskeletal protein, estramustine binding to, in prostate cancer cell (human), 866

D

- Daunorubicin, cytotoxicity of (yeast), 1234
 Daunorubicin-binding protein, down-regulation of, in liver tumor (mouse), 896
 Deoxycoformycin, dideoxyadenosine metabolism and (human), 1002

- Deoxyribonucleic acid, mitochondrial, in lymphoblast, quantitation of (human), 1063
 Dideoxyadenosine, metabolism of, deoxycoformycin and (human), 1002
 Dideoxynucleosides, hydroxyurea with, anti-HIV activity of (human), 767
 Diethylthiocarbamate methyl ester, glutathione-S-transferase-dependent desulfuration of (rat), 1217
 Dihydropyridine, potassium current inhibition by (bovine), 743
 Dihydropyridine binding domain, of L-type calcium channel (guinea pig), 660
 Dopamine autoreceptor, cocaine motor actions and (rat), 51
 Dopamine receptor
 2-aminotetralin binding to (human), 299
 agonist affinity at (hamster), 352
 native and mutant forms of (human and rat), 364
 Dopamine reuptake transporter protein, radiation inactivation of (rat), 726
 Doxorubicin, cytotoxicity of (yeast), 1234
 Doxorubicin-induced DNA degradation, in thymocyte (mouse), 901

E

- EGF, *see* Epidermal growth factor
 Endothelial cell, vascular, adhesion molecule expression on, gold sodium thiomalate and (human), 599
 Endothelin receptor
 in mesangial cells (rat), 41
 signal transduction and, in myometrium (rat), 485
 Epidermal growth factor, somatostatin receptors and, in pancreatic cancer cell (rat), 97
 Epidermal growth factor-urogastrone receptor, intestinal (guinea pig), 256
 Epithelial cell, EGF-urogastrone receptors in (guinea pig), 256
 Estramustine, binding of, to cytoskeletal protein, in prostate cancer cell (human), 866
 Ethanol-responsive gene, neural, glucose-regulated protein molecular chaperones and (mouse), 873
 Ether, QX-222 interactions with, in acetylcholine receptor channel (BC3H-1 cells), 169
 Etoposide
 apoptosis by
 in fibroblast (mouse), 890
 in leukemia cell (human), 605
 resistance to
 topoisomerase II mutations and (yeast), 773
 topoisomerase phosphorylation in (human), 58

F

- Fatty acid, gene expression and, in preadipose cell (rat), 1070
 Fibroblast
 etoposide-mediated apoptosis in (mouse), 890
 growth of, protein kinase C inhibitor and (human), 445
 Flavoenzyme, iodonium compound inhibition of (rabbit), 778
 Flunitrazepam, binding of, neuroactive steroid modulation of (rat), 977
 1-(2'-Fluoro-2'-deoxy- β D-arabinofuranosyl)-5-iodouracil, metabolism and effects of (human), 1204
 Forebrain, IGRS in (rabbit), 15
 Forskolin, labeling sites for, on P-glycoprotein (mouse), 329

G

- GABA, *see* γ -Aminobutyric acid
 Gastrin receptor antagonist, L-740,093 as (guinea pig), 943
 Gastrin-releasing peptide receptor
 cAMP increases and (mouse), 235

internalization of, phospholipase C and (mouse), 495
 Geldanamycin, breast cancer cell resistance to (human), 677
 GF 109203X, skin cell growth and (human), 445
 GH₄C₁ cell, guanine nucleotide exchange in, 644
 Glucose-regulated protein molecular chaperone, neural cell ethanol-responsive gene and (mouse), 873
 Glutamate recognition site, interaction of, with glycine recognition site, on NMDA receptor (rat), 1191
 Glutamate uptake, arachidonic acid and oxygen radical inhibition of (rat), 986
 γ-Glutamylcysteine synthetase, in melphalan-resistant prostate carcinoma cell (human), 909
 Glutathione, transport of, in liver, thiol and (rat), 578
 Glutathione-S-transferase-dependent desulfuration, of diethyldithiocarbamate methyl ester (rat), 1217
 Glycine receptor, strychnine-sensitive, zinc and (human), 1156
 Glycine recognition site, interaction of, with glutamate recognition site, on NMDA receptor (rat), 1191
 Glycoprotein, forskolin and prazosin labeling sites on (mouse), 329
 Glycosylation, of GABA receptor (human), 858
 GMP, *see* Guanosine monophosphate
 GnRH, *see* Gonadotrophin-releasing hormone
 Gold, collagenase gene expression and (human), 1084
 Gold sodium thiomalate, adhesion molecule expression and (human), 599
 Gonadotrophin-releasing hormone receptor, G-protein regulation by (mouse), 1
 G-protein
 activation of, rhodopsin and (bovine), 1036
 C5a receptor coupling to (human), 832
 GnRH receptor regulation of (mouse), 1
 thromboxane A₂ receptor reconstitution with (human and mouse), 808
 G-protein-coupled receptor, phospholipase C stimulation by (human and mouse), 460
 Growth factors, angiotensin receptor regulation by, in vascular smooth muscle (rat), 653
 GRP, *see* Gastrin-releasing peptide
 Guanine nucleotide exchange, in GH₄C₁ cells, 644
 Guanosine monophosphate, cyclic
 neurotensin receptor-mediated synthesis of, nitric oxide and (human and rat), 115
 vasodilator-stimulated phosphoprotein phosphorylation by (human), 283

H

Halogenated compound, GABA receptor currents and (*Xenopus*), 851
 Halothane, liver exposed to, heat shock protein 72 and trifluoroacetyl adducts in (rat), 639
 Heat shock protein 72, in halothane-exposed liver (rat), 639
 Hematopoietic cell, suramin-treated, *c-myc* expression and (human), 73
 Hematopoietic progenitor cell, peroxidase activity in (human and mouse), 346
 Hepatoma cell, cytochrome P450 2C6 gene in, transcriptional regulation of (rat), 79
 Herbimycin A, breast cancer cell resistance to (human), 677
 Hippocampus, sodium channels in, phenytoin block of (rat), 716
 Histamine, NMDA receptor and (*Xenopus*), 531
 Human immunodeficiency virus
 deoxycoformycin and (human), 1002
 hydroxyurea and dideoxynucleoside activity against (human), 767, 1002
 Hydrocarbon
 anesthetic, GABA receptor currents and (*Xenopus*), 851
 polycyclic aromatic, cytochrome P450 induction by, cytokines and (human), 1100

3α-Hydroxy-5β-pregnan-20-one sulfate, NMDA response and (chick), 146
 Hydroxyethyl radical-protein adduct immunogenicity (rabbit), 786
 Hydroxylamine, potassium channel block by (*Xenopus*), 970
 Hydroxytryptamine 1 and 2 receptor, kinetics of, in brain (rat), 1111
 Hydroxytryptamine 2 receptor
 cloning and expression of (human), 227
 signal transduction in (hamster), 477
 Hydroxytryptamine 2C receptor, binding properties of (human), 937
 Hydroxytryptamine 3 receptor
 biguanine derivatives at (rat), 732
 Ca²⁺ permeability of (human), 1120
 Hydroxyurea, dideoxynucleosides with, anti-HIV activity of (human), 767

I

IGRS, *see* Imidazoline/guanidinium receptive site
 Imidazoline/guanidinium receptive site, functionalized ligands for (rabbit), 15
 Inositol phosphates
 accumulation of, endothelin receptor and, in myometrium (rat), 485
 substance P receptor regulation by (*Xenopus*), 380
 Inositol 1,4,5-trisphosphate, generation of, lithium and (hamster), 1138
 Interleukin-1, mitogen-activated protein kinase activation by, in leukemia cell (human), 1077
 Iodonium, flavoenzyme inhibition by (rabbit), 778

K

Keratinocyte
 9-anthrone inhibition of (human), 186
 growth of, protein kinase C inhibitor and (human), 445
 protein kinase C regulation in, byrostatin and (mouse), 840
 [³H]KF17837S, binding of, to brain (rat), 817
 Kidney, IGRS in (rabbit), 15

L

L-740,093, biological properties of (guinea pig), 943
 Leukemia cell
 etoposide-mediated apoptosis of (human), 605
 etoposide-resistant, topoisomerase phosphorylation in (human), 58
 mitogen-activated protein kinase in, interleukin-1 activation of (human), 1077
 protein kinase C activation and *c-jun* expression in, arabinofuranosylcytosine and (human), 67
 Leukemic lymphoblasts, multidrug resistance pump in, quinine epoxide inhibition of (human), 563
 [³H]LF 7-0156, for angiotensin II receptor (rabbit), 693
 Lincomycin, peptidyltransferase inhibition by (*Escherichia coli*), 1009
 Lipid disordering, anesthetic-induced acetylcholine receptor desensitization and (*Torpedo*), 508
 Lipoprotein, low density, binding of, in vascular smooth muscle cells (human), 1129
 Lithium, phosphatidylinositol 4,5-bisphosphate and inositol 1,4,5-trisphosphate metabolism and (hamster), 1138
 Liver
 cytochrome P450 hydroxylation of bufuralol in (human), 568
 DNA-binding form of aryl hydrocarbon receptor in (rat), 1022
 glutathione transport in, thiol and (rat), 578
 halothane-exposed, heat shock protein 72 and trifluoroacetyl adducts in (rat), 639
 IGRS in (rabbit), 15
 monoamine oxidase cDNA in (trout), 1226

- pancreastatin receptors in (rat), 24
- Liver tumor, daunorubicin-binding protein regulation in (mouse), 896
- Lymphoblast
 - leukemic, multidrug resistance pump in, quinine epoxide inhibition of (human), 563
 - mitochondrial DNA in, quantitation of (human), 1063

M

- Melanocortin receptor, melanocortin peptides and (human), 1182
- Melphalan, prostate cancer cell resistant to, γ -glutamylcysteine synthetase in (human), 909
- Mephenytoin, polymorphism of, genetic defect in (human), 594
- Mesangial cell, endothelin receptors in (rat), 41
- Mesothelioma cell growth, modulation of, by hammerhead ribozyme (human), 437
- 2-Methyl-2-nitrosopropane, nitric oxide generation from (mouse), 709
- Mitochondrial DNA, in lymphoblasts, quantitation of (human), 1063
- Mitogen-activated protein kinase, in leukemia cell, interleukin-1 activation of (human), 1077
- Mitoxantrone, cytotoxicity of (yeast), 1234
- Monoamine oxidase, hepatic (trout), 1226
- Multidrug resistance pump, quinine epoxide inhibition of, in leukemic lymphoblasts (human), 563
- Muscarinic receptor
 - allosteric binding to (rat), 685
 - allosteric interactions at (rat and rabbit), 105
 - M4 (m4) subtype of (hamster), 1028
 - phosphatidylinositol and inositol phosphate metabolism and, lithium and (human), 1138
 - phospholipase D desensitization and (human), 406
- Muscle
 - ryanodine receptor in, quantal calcium release from (rabbit), 502
 - skeletal
 - aging, ATP-sensitive potassium channels in (rat), 754
 - embryonic acetylcholine receptors in, GABA block of (rat), 1197
 - smooth, *see* Smooth muscle
- Myelin lipid bilayer, chloride/hydroxyl ion exchange through, thallium and (human), 1210
- Myometrium, signal transduction in, endothelin receptor and (rat), 485

N

- Nephrotoxicity data, NMR-generated, pattern recognition analysis of (rat), 199
- Neural cell, ethanol-responsive gene in, glucose-regulated protein molecular chaperones and (mouse), 873
- Neurokinin receptor, phospholipase C activation by, protein kinase C and (human), 266
- Neurokinin receptor antagonist, species selectivity of (human and rat), 122
- Neuronal γ -aminobutyric acid transporter in LLC-PK₁ cells, 550
- Neuropeptide, release of, GABA receptor and (rat), 558
- Neurotensin receptor
 - cGMP synthesis and, nitric oxide and (human and rat), 115
 - deletion mutation in, polyphosphoinositide hydrolysis and (rat), 470
- Nitric oxide
 - adenylyl cyclase and protein kinase C and (rat), 274
 - generation of, from 2-methyl-2-nitrosopropane (mouse), 709
 - neurotensin receptor-mediated cGMP synthesis and (human and rat), 115
 - production of, endotoxic shock and (rat), 391
- NMDA, *see* N-methyl-D-aspartate
- N-methyl-D-aspartate receptor

- glutamate and glycine recognition site interaction in (rat), 1191
- histamine and (*Xenopus*), 531
- recombinant, spermine and (*Xenopus*), 161
- N-methyl-D-aspartate receptor channel, aminoacridine blockade of, Mg²⁺ and (rat), 151
- N-methyl-D-aspartate response, 3 α -hydroxy-5 β -pregnan-20-one sulfate and (chicken), 146
- NMR, *see* Nuclear magnetic resonance
- Nucleotide-dependent potassium channel, opioid receptor modulation of (bovine), 793

O

- Opioid receptor
 - δ -type (human), 1015
 - μ -type, nucleotide-dependent potassium channel modulation by (bovine), 793
- Organogenesis, cytochrome P450 03A gene in (human), 922
- Oxygen radicals, glutamate uptake and (rat), 986

P

- Pancreastatin receptor, hepatic (rat), 24
- Pancreatic cancer cell, somatostatin receptor in, EGF and (rat), 97
- Peptidyltransferase, lincomycin inhibition of (*Escherichia coli*), 1009
- Peroxidase, in hematopoietic progenitor cells (human and mouse), 346
- P-glycoprotein, forskolin and prazosin labeling sites on (mouse), 329
- P-glycoprotein substrate, rhodamine efflux pattern prediction of (human), 627
- Phenytoin, hippocampal sodium channel block by (rat), 716
- Pheochromocytoma, cyclic AMP regulation of secretogranin II and chromogranin B in (rat), 880
- Phorbol ester-resistant leukemia cell, protein kinase C and c-jun expression in, arabinofuranosylcytosine and (human), 67
- Phosphatidylinositol 4,5-bisphosphate metabolism, lithium and (hamster), 1138
- Phosphodiesterases, multiple (mouse and rat), 399
- Phospholipase C
 - gastrin-releasing peptide receptor internalization and (mouse), 495
 - neurokinin receptor activation of, protein kinase C and (human), 266
 - protein G-coupled receptor stimulation of (human and mouse), 460
 - purinergic receptor coupling to (turkey), 8
- Phospholipase D, desensitization of (human), 406
- Phosphoprotein, vasodilator-stimulated, phosphorylation of, by transfected cGMP (human), 283
- Picrotoxin, embryonic acetylcholine receptor block by (rat), 1197
- Platelet-derived growth factor- β , modulation of, by hammerhead ribozyme (human), 437
- Pneumocystis carinii*, butamidine drugs for (human), 313
- Polycyclic aromatic hydrocarbon, cytochrome P450 induction by, transforming growth factor- β and (human), 1100
- Polyphosphoinositide, hydrolysis of, neurotensin receptor deletion mutation and (rat), 470
- Potassium channel
 - ATP-sensitive
 - blockers of, U-37883A as (*Xenopus*), 139
 - in skeletal muscle fiber, aging and (rat), 754
 - trypsin and (rat), 176
 - clofilium and hydroxylamine block of (*Xenopus*), 970
 - inactivation of, aminopyridine and (rat), 1175
 - nucleotide dependent, μ -opioid receptor modulation of (bovine), 793
 - voltage-gated, bretylium tosylate block of (human), 762
- Potassium current
 - chloride channel blocker regulation of (human), 750

- dihydropyridine inhibition of (bovine), 743
 Prazosin, labeling sites for, on P-glycoprotein (mouse), 329
 Preadipose cell, gene expression in, fatty acid and thiazolidinedione and (rat), 1070
 Prostaglandin receptor, EP₂ subtype of (human), 213
 Prostate cancer cell
 estramustine binding to cytoskeletal protein in (human), 866
 melphalan-resistant, γ -glutamylcysteine synthetase in (human), 909
 Protein kinase C
 arabinofuranosylcytosine and, in leukemia cell (human), 67
 isozymes of, bryostatin binding to (Sf9 insect), 374
 and neurokinin receptor activation of phospholipase C (human), 266
 nitric oxide production and (rat), 274
 bryostatin regulation of (mouse), 840
 Protein kinase C inhibitor, skin cell growth and (human), 445
 Protein kinase I β , phosphoprotein phosphorylation and (human), 283
 Purinergic receptor, coupling of, to phospholipase C (turkey), 8

Q

- Quinine epoxide, multidrug resistance pump inhibition by, in leukemic lymphoblasts (human), 563
 Quinpirole, dopamine receptor affinity for (hamster), 352
 QX-222, general anesthetic interactions with, in acetylcholine receptor channel (BC3H-1 cells), 169

R

- Radiation, dopamine reuptake transporter protein inactivation by (rat), 726
 Retinaldehyde, conversion of, cytosolic and mitochondrial aldehyde dehydrogenase and (mouse), 88
 Rhodamine, efflux patterns of, P-glycoprotein substrate prediction by (human), 627
 Rhodopsin, G-protein activation and (bovine), 1036
 Ro5-4684 binding site, amino acids and (human), 1160
 Ryanodine receptor, in muscle, quantal calcium release from (rabbit), 502

S

- [³H]SB 206606, as β -Adrenergic receptor radioligand (hamster), 357
 Secretogranin II, cyclic AMP regulation of, in pheochromocytoma (rat), 880
 Serotonin transporter, ligand recognition domain identification by (human and rat), 799
 Shock, endotoxic, nitric oxide production and (rat), 391
 Signal transduction, lipoprotein-induced, in vascular smooth muscle (human), 1129
 Skeletal muscle
 aging, ATP-sensitive potassium channels in (rat), 754
 embryonic acetylcholine receptors in, GABA block of (rat), 1197
 Skin cell growth, protein kinase C inhibitor modulation of (human), 445
 SK-N-MC cell, α_1 -adrenergic receptors in (human), 221
 Smooth muscle
 EGF-urogastrone receptors in (guinea pig), 256
 vascular, *see* Vascular smooth muscle
 Smooth muscle membrane, ileal, iodinated bradykinin discrimination among bradykinin receptor subtypes in (guinea pig), 949
 Sodium channel, hippocampal, phenytoin block of (rat), 716
 Somatostatin, release of, GABA receptor and (rat), 558
 Somatostatin receptor
 EGF regulation of, in pancreatic cancer cell (rat), 97

- subtypes of (human), 291
 Spermine, NMDA recombinant receptors and (*Xenopus*), 161
 Spiriform nucleus, lateral, nicotinic receptor heterogeneity in (avian), 993
 SSTR5, characterization of (human), 291
 Striatum, activator protein-1 in, cocaine and (rat), 667
 Strychnine-sensitive glycine receptor, zinc and (human), 1156
 Substance P, nicotinic acetylcholine receptor photoaffinity labeling with (*Torpedo*), 1048
 Substance P receptor, inositol pentakis- and hexakisphosphate regulation of (*Xenopus*), 380
 Sulfonylurea receptor, trypsin and (rat), 176
 Suramin, *c-myc* expression and, in hematopoietic cell (human), 73

T

- Thallium, as chloride/hydroxyl ion exchange ionophore (human), 1210
 Thiazolidinedione, gene expression and, in preadipose cell (rat), 1070
 Thiol, hepatic glutathione transport and (rat), 578
 Thrombin receptor, phospholipase D desensitization and (human), 406
 Thromboxane A₂ receptors, reconstitution of, with G-proteins (human and mouse), 808
 Thymocyte, doxorubicin-induced DNA degradation in (mouse), 901
 Topoisomerase II
 in cellular resistance to cisplatin (mouse), 431
 in DC-3F/9-OH-E cells (hamster), 323
 mutations of, etoposide and amsacrine resistance and (yeast), 773
 phosphorylation of, in etoposide-resistant leukemia cells (human), 58
 Transforming growth factor- β , polycyclic aromatic hydrocarbon-induced cytochrome P induction and (human), 1100
 Trifluoroacetyl adduct, in halothane-exposed liver (rat), 639
d-Tubocurarine, drugs competing with, for cardiac muscarinic receptor binding (rat), 685
 Tyrosine hydroxylase, Ca²⁺/calmodulin-dependent kinase activation and, in adrenal medulla (bovine), 1041

U

- U-37883A, as ATP-sensitive potassium channel blocker (*Xenopus*), 139
 Urogastrone receptor, intestinal (guinea pig), 256

V

- Vascular endothelial cell, adhesion molecule expression on, gold sodium thiomalate and (human), 599
 Vascular smooth muscle
 α_1 -adrenoceptors in (rat), 30
 angiotensin receptor in, growth factors and (rat), 653
 low density lipoprotein binding in (human), 112
 nitric oxide production by, adenylyl cyclase and protein kinase C and (rat), 274
 Vasodilator-stimulated phosphoprotein, phosphorylation of, by transfected cGMP (human), 283
 Vimentin, filaments of, withangulatin A and (rat), 612
 Voltage-gated potassium channel, bretylium tosylate block of (human), 762

W

- WIN 51708, species selectivity of (human and rat), 122
 Withangulatin A, vimentin intermediate filaments and (rat), 612

Z

- Zinc, strychnine-sensitive glycine receptor and (human), 1156

STATEMENT OF OWNERSHIP MANAGEMENT AND CIRCULATION (Required by 39 U.S.C. 3685)

1. Title of publication: MOLECULAR PHARMACOLOGY; 2. Publication no.: 0026-689X.
3. Date of filing: 10-01-94 4. Frequency of issue: Monthly; 5. No. of issues published annually: 12; 6. Annual subscription price: \$105.00. 7. Complete mailing address of known office of publication: 428 E. Preston Street, Baltimore, MD 21202-3993.
8. Complete mailing address of the headquarters of general business offices of the publisher: 428 E. Preston Street, Baltimore, MD 21202-3993.
9. Full names and complete mailing address of publisher, editor, and managing editor: Publisher: Williams & Wilkins, 428 E. Preston Street, Baltimore, MD 21202-3993; Editor: Dr. T. Kendall Harden, CB #7368, Dept. of Pharmacology, University of North Carolina, School of Medicine, Chapel Hill, NC 27599-7368. Managing Editor: N/A.
10. Owner: American Society of Pharmacology and Experimental Therapeutics, c/o Kay Croker, Executive Director, 9650 Rockville Pike, Bethesda, MD 20814.
11. Known bondholders, mortgagees, and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages, or other securities: None.
12. Purpose, function, and nonprofit status: Has not changed during preceding 12 months.
13. Publication Name: MOLECULAR PHARMACOLOGY
14. Issue Date for circulation data: August, 1994.
15. Extent and nature of circulation: Average number of copies each issue during preceding 12 months: (A) Total no. copies (Net Press Run), 2305. (B) Paid and/or requested circulation; (1) Sales through dealers and carriers, street vendors and counter sales (not mailed), 201; (2) Paid or Requested mail subscriptions (include Advertisers Proof Copies/Exchange Copies), 1375. (C) Total paid and/or requested circulation (sum of 15b1 and 15b2), 1576. (D) Free distribution by mail (samples, complimentary, and other free copies), 90. (E) Free distribution outside the mail (carriers or other means), none. (F) Total free distribution (sum of 15d and 15e), 90. (G) Total distribution (Sum of 15c and 15f) 1666. (H) Copies not distributed: (1) Office use, leftovers, spoiled, 639; (2) Return from news agents, none. (I) Total (sum of 15g, 15h(1), and 15h(2)) 2305. Percent Paid and/or Requested Circulation ($15c/15g \times 100$) 94.5%. Actual no. copies of single issue published nearest to filing date: (A) Total no. copies (Net Press Run), 2070. (B) Paid and/or requested circulation; (1) Sales through dealers and carriers, street vendors and counter sales (not mailed), 209; (2) Paid or Requested mail subscriptions (include Advertisers Proof Copies/Exchange Copies), 1310. (C) Total paid and/or requested circulation (sum of 15b1 and 15b2), 1519. (D) Free distribution by mail (samples, complimentary, and other free copies), 92. (E) Free distribution outside the mail (carriers or other means), none. (F) Total free distribution (sum of 15d and 15e), 92. (G) Total distribution (Sum of 15c and 15f), 1611. (H) Copies not distributed: (1) Office use, leftovers, spoiled, 459; (2) Return from news agents, none. (I) Total (sum of 15g, 15h(1), and 15h(2)), 2070. Percent Paid and/or Requested Circulation ($15c/15g \times 100$), 94.3%.
16. This Statement of Ownership will be printed in the December, 1994 issue of this publication.
17. I certify that the statements made by me above are correct and complete.

Alma J. Wills
Publisher

**Copyright © 1994 by the American Society for
Pharmacology and Experimental Therapeutics**

Leading Pharmacology Journals

Publications of the American Society for Pharmacology and Experimental Therapeutics, Inc.

The Journal of Pharmacology and Experimental Therapeutics

Editor: John A. Harvey, Ph.D.

JPET is respected the world over as one of the leading research journals in the field of pharmacology. You'll find broad coverage of all aspects of the interactions of chemicals with biological systems, including autonomic, behavioral, cardiovascular, cellular, clinical, developmental, gastrointestinal, immuno-, neuro-, pulmonary, and renal pharmacology, as well as analgesics, drug abuse, metabolism and disposition, chemotherapy, and toxicology. *Monthly.*

Drug Metabolism and Disposition: the biological fate of chemicals

Editor: Raymond F. Novak, Ph.D.

Drug Metabolism and Disposition publishes experimental results from *in vitro* and *in vivo* systems that bring you significant and original information on metabolism and disposition of endogenous and exogenous compounds, including pharmacologic agents and environmental chemicals. The areas covered are: xenobiotic metabolism, expression of drug metabolizing enzymes, regulation of drug metabolizing enzyme gene expression, pharmacokinetics, pharmacodynamics and toxicological consequences of xenobiotic metabolism. *Monthly.*

Pharmacological Reviews


Editor: Robert E. Stitzel, Ph.D.

Pharmacological Reviews is a showcase for important review articles in your field, featuring longer papers on topics of high current interest. The areas covered in review papers have included biochemical and cellular pharmacology, drug metabolism and disposition, renal pharmacology, neuropharmacology, behavioral pharmacology, clinical pharmacology, and toxicology. No library serving the pharmacologic community should be without a subscription. *Quarterly.*

Molecular Pharmacology

Editor: Raymond Dingle, Ph.D.

The papers published in **Molecular Pharmacology** are on the cutting edge of research on drug action and selective toxicity at the molecular level. Original applications of biochemistry, biophysics, genetics, and molecular biology are juxtaposed with innovative pharmacologic research to elucidate basic problems in pharmacology and toxicology, including such areas as molecular mechanisms involved in drug receptor-effector coupling, xenobiotic metabolism, and antibiotic and anticancer drug action. *Monthly.*



MEMBERS:

SAVE 10% when ordering two
SAVE 15% when ordering three
SAVE 20% when ordering four



Please enter my subscription to the following:

The Journal of Pharmacology and Experimental Therapeutics (monthly)

☐ Individual \$190/year ☐ Institutional \$340/year (Add \$65/year for subscriptions outside the U.S.; in Canada, also add 7% GST.)
☐ New Subscription ☐ Renewal
Subscribe for: ☐ 3 years ☐ 2 years ☐ 1 year

Drug Metabolism and Disposition (monthly)

☐ Individual \$85/year ☐ Institutional \$140/year (Add \$20/year for subscriptions outside the U.S.; in Canada, also add 7% GST.)
☐ New Subscription ☐ Renewal
Subscribe for: ☐ 3 years ☐ 2 years ☐ 1 year

Molecular Pharmacology (monthly)

☐ Individual \$105/year ☐ Institutional \$230/year (Add \$30/year for subscriptions outside the U.S.; in Canada, also add 7% GST.)
☐ New Subscription ☐ Renewal
Subscribe for: ☐ 3 years ☐ 2 years ☐ 1 year

Pharmacological Reviews (quarterly)

☐ Individual \$60/year ☐ Institutional \$107/year ☐ In-training * \$45/year (Add \$15/year for subscriptions outside the U.S.; in Canada, also add 7% GST.)
☐ New Subscription ☐ Renewal
Subscribe for: ☐ 3 years ☐ 2 years ☐ 1 year

PTT 55769

Payment Options:

☐ Check enclosed (payable to Williams & Wilkins)
☐ Bill me ☐ American Express
☐ MasterCard ☐ VISA Card # _____
Exp. date _____ Signature or P.O. # _____

Name _____
Address _____
City/State/Zip _____
* Please indicate institution/status _____

MD subscribers must add state sales tax. Subscriptions outside the U.S. must be prepaid in U.S. dollars. In Japan, contact Igaku-Shoin, MYW, Ltd. (03) 5689-5400. Rates valid through October 31, 1995.

Return coupon to:
Williams & Wilkins
A WAVERLY COMPANY

P.O. Box 23291, Baltimore, MD 21203-9990

For credit card orders, call TOLL FREE:
1-800-638-6423 in the U.S. or Canada.

J5069S ZPTT

An important resource for everyone
involved in research on the
metabolism of drugs and chemicals

DRUG METABOLISM AND DISPOSITION


The Biological Fate of Chemicals

Editor: Raymond F. Novak, Ph.D., Wayne State University, Detroit, Michigan

DRUG METABOLISM AND DISPOSITION publishes experimental results from *in vitro* and *in vivo* systems that bring readers significant and original information on the metabolism and disposition of endogenous and exogenous compounds, including the metabolism of therapeutic agents and environmental chemicals. The journal also invites timely reviews, short communications and letters to the Editor. All submissions are refereed to ensure a high standard of publication. The areas covered are:

- metabolism, metabolite identification and mechanisms of metabolite formation
- expression of drug metabolizing enzymes
- regulation of drug metabolizing enzyme gene expression
- toxicological consequences of xenobiotic metabolism
- pharmacokinetics
- pharmacodynamics

This journal should be a standard reference in all pharmacology and toxicology departments. It is also a valuable resource for all medicinal chemists involved in drug design and all biochemists with interest in drug metabolism, expression or drug metabolizing enzymes and regulation of drug metabolizing enzyme gene expression. *Monthly*



YES! Enter my subscription:

Avoid future rate increases and ensure uninterrupted service — enter your multiyear subscription today!

Drug Metabolism and Disposition (monthly)

- ☐ Individual: \$85/yr ☐ Institutions: \$140/yr
(Please add \$20.00 outside the U.S.; in Canada, also add 7% GST.)
☐ New Subscription ☐ Renewal ☐ 3 yrs ☐ 2 yrs ☐ 1 yr

name _____

address _____

city/state/zip _____

Payment options:

- ☐ Check enclosed ☐ Bill me
☐ VISA ☐ MasterCard ☐ American Express

card # _____

signature/P.O. # _____

MD subscribers must add state sales tax. Subscriptions from outside the US and Canada must be prepaid, in US dollars only. In Japan, contact Igaku-Shoin MYW, Ltd. (03) 5689-5400. Rates valid for orders received before October 31, 1995.

Please allow 8 weeks for delivery of your first issue. Surface mail delivery to countries outside the US may take up to 16 weeks. Airmail rates available upon request.

Discounts available to members on all ASPET publications. SAVE 10% when ordering two. SAVE 15% when ordering three. SAVE 20% when ordering all four.

Williams & Wilkins
A WAVERLY COMPANY

DMD 55716

P.O. Box 23291
Baltimore, Maryland 21203-9990

Printed in USA


Broadway House
2-6 Fulham Broadway
London SW6 1AA England

J5016S ZDMD



Previous Editors

- 1965** Avram Goldstein, *Editor*. Stanford University.
- 1968** Paul Talalay, *Editor*; Donald S. Coffey, *Associate Editor*. Johns Hopkins University.
- 1971** Steven E. Mayer, *Editor*, Palmer W. Taylor, *Associate Editor*. University of California at San Diego.
- 1975** George I. Drummond, *Editor*; H. Joseph Goren, *Associate Editor*. University of Calgary.
- 1978** Norman Kirschner, *Editor*; Theodore A. Slotkin, *Associate Editor*. Duke University.
- 1983** Joel G. Hardman, *Editor*; Lee Limbird, F. Peter Guengerich, *Associate Editors*. Vanderbilt University.
- 1986** William A. Catterall, *Editor*; Joseph A. Beavo, Mont R. Juchau, Neil M. Nathanson, Daniel R. Storm, Frank F. Vincenzi, *Associate Editors*. University of Washington, Seattle.



Williams & Wilkins Quick Copies. Tell us today. Read it tomorrow.

You can get copies of any article published in any Williams & Wilkins journal. It's fast — because we're the primary source, we can fax an article to you within **24 hours** of when we receive your request. It costs less — there are **no copyright fees** and the **cost of faxing is included in the price**. It's affordable — look at the table to the right.

RATES, PER ARTICLE

1–5	pages	\$10
6–10	pages	\$12
11–15	pages	\$15
16–20	pages	\$18
21–25	pages	\$20
26+	pages	\$25

(\$20, Federal Express)

Fax, phone, or mail your citation to:

**Williams & Wilkins
Quick Copies**

428 East Preston Street

Baltimore, MD 21202-3993

Call 1-800-354-9685 (toll free)

Fax 1-410-528-4312



Williams & Wilkins

A WAVERLY COMPANY

DDSAD 55429

#1 for
impact among all
peer-reviewed
pharmacology journals
—SCI, 1993

Newsworthy and timely articles keep you up-to-date in your field.

MOLECULAR PHARMACOLOGY

Editor: **Raymond Dingledine, Ph.D.**
Emory University School of Medicine
Atlanta, Georgia


Is your special interest receptors and neurotransmitters...drug metabolism...antibiotic and anticancer drug actions...or other areas related to molecular basis of drug action? If so, you should be subscribing to **MOLECULAR PHARMACOLOGY**.

The editor's and editorial board's high standards ensure that the papers you read in **MOLECULAR PHARMACOLOGY** are on the cutting edge of research on drug action and selective toxicity at the molecular level. Original applications of biochemistry, biophysics, genetics, and molecular biology are juxtaposed with innovative pharmacologic research to elucidate basic problems in pharmacology and toxicology, including such areas as molecular mechanisms involved in drug receptor-effector coupling, xenobiotic metabolism, and antibiotic and anti-cancer drug action. Start your subscription today to ensure access to the most newsworthy papers in your field. *Monthly*

Cut out and send in the coupon or call toll-free to start your subscription immediately,
1-800-638-6423 from anywhere in the U.S. or Canada.



Williams & Wilkins
A WAVERLY COMPANY



YES! Enter my subscription.

Avoid future rate increases and ensure uninterrupted service—enter your multiyear subscription today!

MOLECULAR PHARMACOLOGY(monthly)

☐ Individual: \$105/yr ☐ Institution: \$230/yr
(Please add \$30.00 outside the U.S.; Canada, also add 7% GST.)

☐ New Subscription ☐ Renewal
☐ 3 yrs ☐ 2 yrs ☐ 1 yr

Name

Address

City/State/Zip

Payment Options:

☐ Check enclosed (payable to Williams & Wilkins)
☐ Bill me ☐ American Express
☐ MasterCard ☐ VISA

Card # Exp. date

Signature or P.O. #

MD subscribers must add state sales tax. Subscriptions outside the U.S. must be prepaid in U.S. dollars. In Japan, contact Igaku-Shoin, MYW, Ltd. (03) 5689-5400. Rates valid through October 31, 1995.

Please allow 8 weeks for delivery of your first issue. Surface mail delivery to countries outside the U.S. may take up to 16 weeks. Airmail rates available upon request.

Discounts available to members on all ASPET publications. SAVE 10% when ordering two. SAVE 15% when ordering three. SAVE 20% when ordering all four.

Williams & Wilkins

P.O. Box 23291
Baltimore, Maryland 21203-9990

Broadway House
2-6 Fulham Broadway
London SW6 1AA England

MOL 55742

Printed in USA

J5042S ZMOL